

# BMJ Open

## Procalcitonin as a predictor of moderate to severe acute respiratory distress syndrome (ARDS) after cardiac surgery with cardiopulmonary bypass (CPB): a study protocol for a prospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006344
Article Type:	Protocol
Date Submitted by the Author:	09-Aug-2014
Complete List of Authors:	Chen, Han; Fujian Provincial Hospital, Surgical Intensive Care Unit Cheng, Zhang-Bo; Fujian Provincial Hospital, Department of Cardiosurgery; Fujian Cardiovascular Research Institute, Yu, Rong-Guo; Fujian Provincial Hospital, Surgical Intensive Care Unit
<b>Primary Subject Heading</b>:	Intensive care
Secondary Subject Heading:	Anaesthesia, Cardiovascular medicine
Keywords:	Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Cardiac surgery < SURGERY, Anaesthesia in cardiology < ANAESTHETICS

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Procalcitonin as a predictor of moderate to severe acute respiratory**  
5  
6 **distress syndrome (ARDS) after cardiac surgery with**  
7  
8 **cardiopulmonary bypass (CPB): a study protocol for a prospective**  
9  
10 **cohort study**  
11  
12

13 Han Chen, MD; Zhang-Bo Cheng, MD; Rong-Guo Yu, MD\*

14  
15  
16 Surgical Intensive Care Unit, Fujian Provincial Clinical College of Fujian Medical  
17  
18 University, Fujian Provincial Hospital, Fuzhou, Fujian, 350001, PR China (H.C. and  
19  
20 R.G.Y.) and Department of Cardiosurgery, Fujian Provincial Clinical College of  
21  
22 Fujian Medical University, Fujian Cardiovascular Research Institute, Fuzhou, Fujian,  
23  
24 350001, PR China (ZB.C.)  
25  
26  
27  
28  
29  
30

31 \*: Corresponding author  
32

33 Rong-Guo Yu  
34

35  
36 Surgical Intensive Care Unit, Fujian Provincial Clinical College of Fujian Medical  
37  
38 University, Fujian Provincial Hospital  
39

40 Address: 134 Dongjie Street, Gulou district, Fuzhou, 350001, PR China  
41

42 Telephone: +86 0591 88217010  
43

44 Email: [garyyrg@yahoo.com](mailto:garyyrg@yahoo.com)  
45  
46

47 Email of authors:  
48

49 Han Chen: [baojr2@163.com](mailto:baojr2@163.com)  
50  
51

52 Zhang-Bo Cheng: [16016331@qq.com](mailto:16016331@qq.com)  
53  
54

55 Word count: 1707  
56  
57  
58  
59  
60

## Abstract

**Introduction:** Procalcitonin (PCT) is activated during cardiopulmonary bypass (CPB) and may be a predictor of acute respiratory distress syndrome (ARDS). The object is to validate that whether patients with different serum PCT concentration have different incidence of developing moderate to severe ARDS.

**Methods and analysis:** The study is a prospective, single center, observational cohort study. All patients admitted to the cardiosurgery department who are programmed for a cardiac surgery with CPB are screened for study eligibility. All eligible patients will receive operation with CPB. Blood samples are obtained for test of white blood cell (WBC) count, N-terminal pro-B-type natriuretic peptide (Nt-pro-BNP), C-reactive protein (CRP) and procalcitonin (PCT). Patients are assigned to PCT elevated cohort or control cohort according to serum PCT concentration on the first postoperative day with a cut-off value of 7.0 ng/ml. Data will be collected daily for seven days, which including baseline data, perioperative data and outcomes. The primary endpoint is incidence of moderate to severe ARDS, which is diagnosed according to the Berlin definition.

**Ethics and dissemination:** The study was approved by the Institutional Review Board of Fujian Provincial Hospital. Study findings will be disseminated through peer-reviewed publications and conference presentations.

**Trial registration:** Chinese Clinical Trial Registry (ChiCTR-OCH-14005076).

## Introduction

Epidemiological studies have shown that cardiac surgery is a known risk factor for acute respiratory distress syndrome (ARDS).[1-3] There are more than 300,000 patients who undergo cardiac surgery every year in the United States, as many as 20% will have ARDS.[4] The risk factors include the type of surgery, cardiopulmonary bypass, ischemia-reperfusion injury, transfusion-related acute lung injury and drug toxicity. The mortality rate associated with ARDS is approximately 40% in the general population, but much higher among post-cardiac surgery patients, which may be as high as 80%.[5 6] Moderate to severe ARDS causes the majority of death cases, and the possible therapeutic choices are different in different severity of ARDS. Mild ARDS patients usually need non-invasive treatments, while moderate to severe ARDS patients are more likely in need of more aggressive interventions such as prone positioning, recruitment maneuver, neuromuscular blockage agents, inhaled nitric oxide, high frequency oscillatory ventilation and even extracorporeal membrane oxygenation. It is meaningful to identify patients with moderate to severe ARDS.

Although cardiac surgery with cardiopulmonary bypass (CPB) is considered a highly sterile type of surgery, it can lead to a systemic inflammatory response syndrome (SIRS).[7] The possible causes are the exposure of blood to non-physiological surfaces, ischemia-reperfusion injury due to aortic clamping and extracorporeal circulation,[8] as well as a translocation of endotoxins from gut to the bloodstream after the release of the aortic clamp,[9] which can activate inflammatory cascades similar to those observed in sepsis. Cytokines such as interleukin (IL)-6, IL-8, tumor

1  
2  
3  
4 necrosis factor (TNF)-alpha as well as C-reactive protein (CRP), lipoprotein-binding  
5  
6 protein (LBP) and procalcitonin (PCT) may play an important role in the immune  
7  
8 reaction, while PCT liberation is predominantly depended on the use of CPB.[10]  
9

10  
11 PCT is initially described as an early, sensitive and specific marker for sepsis  
12  
13 associated with bacterial infection.[11] However, it is also increased in clinical  
14  
15 situations without infections such as major surgery, burns, or trauma.[12] Previous  
16  
17 studies suggested that the concentration of serum PCT increased at the end of CPB,  
18  
19 reaching its peak on the first day and then declined rapidly.[7 13] It is also suggested  
20  
21 that significant elevation of PCT level can be observed when complications  
22  
23 presented.[7 14 15] Therefore, we hypothesis that PCT could be a predictor of the  
24  
25 development of ARDS, especially moderate to severe ARDS, in patients undergo  
26  
27 cardiac surgery with CPB. Our aim is to validate that whether patients with different  
28  
29 serum PCT concentration have different incidence of developing moderate to severe  
30  
31 ARDS.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Methods and analysis

### Study design overview

The present study is a prospective, single center, observational cohort study in patients after elective cardiac surgery.

### Study setting and population

The study setting is cardiosurgical intensive care unit (ICU) (20 beds) and cardiosurgery department (118 beds), Fujian Provincial Hospital (2500 beds), Fujian Provincial Clinical College of Fujian Medical University, Fuzhou, China.

All patients admitted to the cardiosurgery department who are programmed for a cardiac surgery under CPB are screened for study eligibility.

Inclusion criteria are:

- 1) Age 18 years and above;
- 2) Programmed cardiac surgery under CPB;
- 3) Be free from active preoperative infection or inflammatory disease (meet all of the following criteria at study entry: leukocyte count  $< 12 \times 10^9/L$ , PCT  $< 0.5$  ng/ml, body temperature  $< 37.5^\circ C$ );
- 4) Able to consent.

Exclusion criteria are:

- 1) History of chronic obstructive pulmonary disease (COPD), asthma or interstitial lung disease (ILD);

- 2) History of lung surgery;
- 3) Pregnant or lactating women;
- 4) Unwillingness of the patient to provide consent;
- 5) Enrolled in another trial.

### **Anesthesia, CPB and perioperative management**

All patients' cardiosurgery undergo with general anesthesia and median sternotomy.

Anticoagulation is obtained by using sodium heparin at a dose of 3 mg/kg for CPB patients. After attaining an activating clotting time (ACT) greater than 480 seconds,

CPB is initiated by using an occlusive roller pump (jostra, Germany) and a membrane oxygenator (affinity7000, American), followed with moderate hypothermia (28°C) and

crystalloid cardioplegic cardiac arrest. Pump flow is about 2.0-2.6 l/min/m<sup>2</sup> during CPB and the mean arterial pressure (MAP) is maintained between 60 and 80 mmHg.

At the end of surgery, protamine is given at a 1:1 ratio for reversal of the heparin effect (to obtain an ACT < 160s). The ventilator is initially set to deliver a tidal

volume around 7-10 ml/kg and a respiratory rate adjusted to maintain an arterial CO<sub>2</sub> pressure (PaCO<sub>2</sub>) between 35 and 40 mmHg during the surgery. Cephazolin is used as

perioperative antibiotic prophylaxis. Patients are monitored postoperatively in the ICU and ventilated until they meet the following criteria:

- 1) Awake and cooperative;
- 2) Adequate recovery of muscle strength;
- 3) Normal tidal volume, normocapnia (end-tidal carbon dioxide 30-45 mmHg),

1  
2  
3  
4 minimum pulse oxygen saturation ( $SpO_2$ )  $\geq$  95% with fraction of inspiration oxygen  
5  
6 ( $FiO_2$ ) 0.5;

7  
8  
9 4) Hemodynamic stability (small dosage of vasopressor support and mean arterial  
10  
11 pressure within 10-15% of baseline);

12  
13  
14 5) No severe arrhythmias;

15  
16 6) No bleeding or indications of re-exploration.

17  
18 Patients' endotracheal tube is removed if they meet the criteria. Patients are  
19  
20 discharged from ICU after successful extubation. In our clinical practice, blood  
21  
22 samples are routinely obtained for test of whole blood routine before and 1 day after  
23  
24 operation, respectively. PCT is also tested before and 1 day after operation.  
25  
26 N-terminal pro-B-type natriuretic peptide (Nt-pro-BNP) and CRP are tested 1 day  
27  
28 after operation. Chest X-ray is routinely obtained before operation, 1 day and 7 days  
29  
30 after operation, respectively. Additional chest X-ray examinations are performed if  
31  
32 patients represent hypoxia due to suspicious infection, pulmonary atelectasis,  
33  
34 pleural effusion or ARDS. Blood gas analysis is tested at least once per day when the  
35  
36 patients are in the ICU. After they are transferred to the routine room, blood gas  
37  
38 analysis is tested when the physicians considered it is necessary, or when patients'  
39  
40  $SpO_2$  cannot be maintained greater than 95% with a  $FiO_2$  of 0.5.  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

### 51 **Follow up and data collection**

52  
53 This is an observational study that no intervention is applied. At study entry, data on  
54  
55 demographic, history of smoking, history of past illness characteristics, diagnosis and  
56  
57  
58  
59  
60



1  
2  
3  
4 the New York Heart Association (NYHA) functional classification [16] are collected.  
5  
6 Type of surgery, duration of operation, CPB and aortic clamping and net fluid balance  
7  
8 during the operation are recorded. The concentration of serum CRP, Nt-pro-BNP and  
9  
10 PCT level on the first postoperative day are also recorded. Patients are assigned to the  
11  
12 PCT elevated cohort or control cohort according to serum PCT concentration on the  
13  
14 first postoperative day with a cut-off value of 7.0 ng/ml. Daily fluid balance and  
15  
16 highest vasoactive-inotropic score (VIS) are calculated. VIS is calculated as dopamine  
17  
18 dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) + dobutamine dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) + 100  $\times$  epinephrine dose  
19  
20 ( $\mu\text{g}/\text{kg}/\text{min}$ ) + 100  $\times$  norepinephrine dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) + 15  $\times$  milrinone dose  
21  
22 ( $\mu\text{g}/\text{kg}/\text{min}$ ) + 10000  $\times$  vasopressin dose (U/kg/min).[17] Data are collected until the  
23  
24 seventh day after operation. ARDS is diagnosed according to the Berlin definition.[18]  
25  
26 A checklist (Table 1) is used to assess the development of moderate to severe ARDS.  
27  
28 Two physicians make the diagnosis independently. Only the patients who are  
29  
30 diagnosed by both two physicians are considered with moderate to severe ARDS.  
31  
32 Echocardiography or pulmonary artery catheter (PAC) is applied to exclude  
33  
34 hydrostatic edema. Physicians who assess the development of ARDS are unaware of  
35  
36 patients' PCT level.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

Table 1 Checklist of ARDS

	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
<b>Timing:</b> Within 1 week of a known clinical insult or new or worsening respiratory symptoms	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>Chest imaging:</b> Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>Origin of edema:</b> Respiratory failure not fully explained by cardiac failure or fluid overload	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>Oxygenation</b>							
<b>Mild:</b> 200 mm Hg < PaO <sub>2</sub> /FiO <sub>2</sub> ≤ 300 mm Hg with PEEP or CPAP ≥ 5 cm H <sub>2</sub> O	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>
<b>Moderate:</b> 100 mm Hg < PaO <sub>2</sub> /FiO <sub>2</sub> ≤ 200 mm Hg with PEEP ≥ 5 cm H <sub>2</sub> O	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>
<b>Severe:</b> PaO <sub>2</sub> /FiO <sub>2</sub> ≤ 100 mm Hg with PEEP ≥ 5 cm H <sub>2</sub> O	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>
Does the patient developed ARDS?	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>

Abbreviations: CPAP, continuous positive airway pressure; FiO<sub>2</sub>, fraction of inspired oxygen; PaO<sub>2</sub>, partial pressure of arterial oxygen; PEEP, positive end-expiratory pressure.

### **PCT determination**

Serum PCT levels were measured by a highly sensitive and specific commercially available immunoluminometric assay kit (Vidasbrahms PCT, mini VIDS, Italy) according to the manufacturer's recommendation. Quantitative measurement allowed determination of PCT concentrations ranging from 0.05 to 200 ng/ml.

### **Study endpoints**

The primary endpoint is incidence of moderate to severe ARDS.

Secondary endpoints include:

- 1) The duration of mechanical ventilation;
- 2) The length of ICU stay;
- 3) Complications after surgery.

### **Sample size**

Primarily, we expect the incidence of moderate to severe ARDS is higher in the PCT elevated group than in the control group. Previous investigations showed the overall morbidity of moderate to severe ARDS was around 0.5%-2% of patients underwent cardiac surgery.[1-3] Our pilot study showed that the incidence could be as high as 15% in the patients with elevated PCT level. Using the Power and Sample Size Calculation program, we will need to investigate 64 exposure subjects and 64 control subjects to be able to reject the null hypothesis. The Type I error probability ( $\alpha$ ) with testing this null hypothesis is 0.05 and Type II error probability ( $\beta$ ) is 0.2.

### Statistical analysis

Baseline characteristics will be summarized by univariate analyses. Categorical variables will be presented as numbers and percentages, and analyzed by the  $\chi^2$ -test. Continuous variables will be checked for normal distribution and presented as mean and standard deviation or median and inter-quartile range as appropriate. Comparison of continuous variables will be performed by using Student's t-test for normally distributed variables and the Mann-Whitney U test for non-normally distributed variables. All tests of significance will be at the 5% significance level, and two-sided. Analyses are performed by using SPSS 19.0 (IBM Corporation, New York, USA).

### **Ethical aspects and informed consent**

The study protocol and consent forms were approved on October 7th, 2014 by the Institutional Review Board of Fujian Provincial Hospital. The study was registered on October 8th, 2014 at the ClinicalTrials.org (ChiCTR-OCH-14005076).

After patient's eligibility for the study is confirmed, the study coordinator will be introduced to the family. The surgeon will make sure the family knows the credentials of the study coordinator, and says that this person is going to discuss a research program being conducted, and the patient is qualified to do so. Every relevant aspect of the project will be described. The study coordinator will stop frequently, ask if there are any questions, and request that the family repeat back in their own words what is being discussed, to make sure they understand. The study coordinator will be especially careful to assure the family that they are free to decline consent without consequences and that they can withdraw consent at any time without impact on treatment. Family members will be provided with contact information for the study coordinator, local co-investigator and the local Ethical Committee. Written consent will be obtained in the presence of a witness.

### **Dissemination plan**

Results of the trial will be submitted to international peer reviewed journal. Results will also be presented at national and international conferences relevant to subject fields.

**Authors' contributions**

HC and RGY participated in the design of the study and drafted the manuscript. ZBC participated in the design of the study. All authors edited the manuscript and read and approved the final manuscript.

**Funding statement:**

This work was supported by grants from the National Clinical Key Specialty (2011170). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests**

The authors declare that they have no competing interests.

## References

1. Milot J, Perron J, Lacasse Y, Letourneau L, Cartier PC, Maltais F. Incidence and predictors of ARDS after cardiac surgery. *Chest* 2001;**119**(3):884-8
2. Christenson JT, Aeberhard JM, Badel P, et al. Adult respiratory distress syndrome after cardiac surgery. *Cardiovascular surgery (London, England)* 1996;**4**(1):15-21
3. Kaul TK, Fields BL, Riggins LS, Wyatt DA, Jones CR, Nagle D. Adult respiratory distress syndrome following cardiopulmonary bypass: incidence, prophylaxis and management. *The Journal of cardiovascular surgery* 1998;**39**(6):777-81
4. Stephens RS, Shah AS, Whitman GJ. Lung injury and acute respiratory distress syndrome after cardiac surgery. *The Annals of thoracic surgery* 2013;**95**(3):1122-9 doi: 10.1016/j.athoracsur.2012.10.024[published Online First: Epub Date]].
5. Weissman C. Pulmonary complications after cardiac surgery. *Seminars in cardiothoracic and vascular anesthesia* 2004;**8**(3):185-211
6. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. *The New England journal of medicine* 2005;**353**(16):1685-93 doi: 10.1056/NEJMoa050333[published Online First: Epub Date]].
7. Prat C, Ricart P, Ruyra X, et al. Serum concentrations of procalcitonin after cardiac surgery. *Journal of cardiac surgery* 2008;**23**(6):627-32 doi: 10.1111/j.1540-8191.2008.00658.x[published Online First: Epub Date]].
8. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. *The Journal of thoracic and cardiovascular surgery* 1994;**108**(4):626-35
9. Rocke DA, Gaffin SL, Wells MT, Koen Y, Brock-Utine JG. Endotoxemia associated with cardiopulmonary bypass. *The Journal of thoracic and cardiovascular surgery* 1987;**93**(6):832-7
10. Franke A, Lante W, Fackeldey V, et al. Pro-inflammatory cytokines after different kinds of cardio-thoracic surgical procedures: is what we see what we know? *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery* 2005;**28**(4):569-75 doi: 10.1016/j.ejcts.2005.07.007[published Online First: Epub Date]].
11. Assicot M, Bohuon C, Gendrel D, Raymond J, Carsin H, Guilbaud J. High serum procalcitonin concentrations in patients with sepsis and infection. *The Lancet* 1993;**341**(8844):515-18
12. Reinhart K, Karzai W, Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. *Intensive care medicine* 2000;**26**(9):1193-200
13. Kallel S, Abid M, Jarraya A, et al. [Kinetics, diagnostic and prognostic value of procalcitonin after cardiac surgery]. *Annales de biologie clinique* 2012;**70**(5):567-80 doi: 10.1684/abc.2012.0745[published Online First: Epub Date]].
14. Dorge H, Schondube FA, Dorge P, Seipelt R, Voss M, Messmer BJ. Procalcitonin is a valuable prognostic marker in cardiac surgery but not specific for infection. *The Thoracic and cardiovascular surgeon* 2003;**51**(6):322-6 doi: 10.1055/s-2003-45425[published Online First: Epub Date]].
15. Kallel S, Jmel W, Jarraya A, Abdenadher M, Frikha I, Karouia A. The role of procalcitonin and N-terminal pro-B-type natriuretic peptide in predicting outcome after cardiac surgery.

1  
2  
3 Perfusion 2012;**27**(6):504-11 doi: 10.1177/0267659112454155[published Online First: Epub  
4 Date]].

- 5  
6 16. AHA medical/scientific statement. 1994 revisions to classification of functional capacity and  
7 objective assessment of patients with diseases of the heart. *Circulation* 1994;**90**(1):644-5  
8  
9 17. Gaies MG, Gurney JG, Yen AH, et al. Vasoactive-inotropic score as a predictor of morbidity and  
10 mortality in infants after cardiopulmonary bypass. *Pediatric critical care medicine : a journal*  
11 *of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and*  
12 *Critical Care Societies* 2010;**11**(2):234-8 doi: 10.1097/PCC.0b013e3181b806fc[published  
13 Online First: Epub Date]].  
14  
15 18. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin  
16 Definition. *JAMA : the journal of the American Medical Association* 2012;**307**(23):2526-33 doi:  
17 10.1001/jama.2012.5669[published Online First: Epub Date]].  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



# BMJ Open

## Procalcitonin as a predictor of moderate to severe acute respiratory distress syndrome (ARDS) after cardiac surgery with cardiopulmonary bypass (CPB): a study protocol for a prospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006344.R1
Article Type:	Protocol
Date Submitted by the Author:	02-Oct-2014
Complete List of Authors:	Chen, Han; Fujian Provincial Hospital, Surgical Intensive Care Unit Cheng, Zhang-Bo; Fujian Provincial Hospital, Department of Cardiosurgery; Fujian Cardiovascular Research Institute, Yu, Rong-Guo; Fujian Provincial Hospital, Surgical Intensive Care Unit
<b>Primary Subject Heading</b>:	Intensive care
Secondary Subject Heading:	Anaesthesia, Cardiovascular medicine
Keywords:	Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Cardiac surgery < SURGERY, Anaesthesia in cardiology < ANAESTHETICS

SCHOLARONE™  
Manuscripts

1  
2  
3  
4 **Procalcitonin as a predictor of moderate to severe acute respiratory**  
5  
6 **distress syndrome (ARDS) after cardiac surgery with**  
7  
8 **cardiopulmonary bypass (CPB): a study protocol for a prospective**  
9  
10 **cohort study**  
11  
12

13 Han Chen, MD; Zhang-Bo Cheng, MD; Rong-Guo Yu, MD\*

14  
15  
16 Surgical Intensive Care Unit, Fujian Provincial Clinical College of Fujian Medical  
17  
18 University, Fujian Provincial Hospital, Fuzhou, Fujian, 350001, PR China (H.C. and  
19  
20 R.G.Y.) and Department of Cardiosurgery, Fujian Provincial Clinical College of  
21  
22 Fujian Medical University, Fujian Cardiovascular Research Institute, Fuzhou, Fujian,  
23  
24 350001, PR China (ZB.C.)  
25  
26  
27  
28  
29  
30

31 \*: Corresponding author  
32

33 Rong-Guo Yu  
34

35  
36 Surgical Intensive Care Unit, Fujian Provincial Clinical College of Fujian Medical  
37  
38 University, Fujian Provincial Hospital  
39

40 Address: 134 Dongjie Street, Gulou district, Fuzhou, 350001, PR China  
41

42 Telephone: +86 0591 88217010  
43  
44

45 Email: [garyyrg@yahoo.com](mailto:garyyrg@yahoo.com)  
46  
47

48 Email of authors:  
49

50 Han Chen: [baojr2@163.com](mailto:baojr2@163.com)  
51

52 Zhang-Bo Cheng: [16016331@qq.com](mailto:16016331@qq.com)  
53  
54

55 Word count: 1707  
56  
57  
58  
59  
60

## Abstract

**Introduction:** Procalcitonin (PCT) is activated during cardiopulmonary bypass (CPB) and may be a predictor of acute respiratory distress syndrome (ARDS). The object is to validate that whether patients with different serum PCT concentration have different incidence of developing moderate to severe ARDS.

**Methods and analysis:** The study is a prospective, single center, observational cohort study. All patients admitted to the cardiosurgery department who are programmed for a cardiac surgery with CPB are screened for study eligibility. All eligible patients will receive operation with CPB. Blood samples are obtained for test of white blood cell (WBC) count, N-terminal pro-B-type natriuretic peptide (Nt-pro-BNP), C-reactive protein (CRP) and procalcitonin (PCT). Patients are assigned to PCT elevated cohort or control cohort according to serum PCT concentration on the first postoperative day with a cut-off value of 7.0 ng/ml. Data will be collected daily for seven days, which including baseline data, perioperative data and outcomes. The primary endpoint is incidence of moderate to severe ARDS, which is diagnosed according to the Berlin definition.

**Ethics and dissemination:** The study was approved by the Institutional Review Board of Fujian Provincial Hospital. Study findings will be disseminated through peer-reviewed publications and conference presentations.

**Trial registration:** Chinese Clinical Trial Registry (ChiCTR-OCH-14005076).

## Introduction

Epidemiological studies have shown that cardiac surgery is a known risk factor for acute respiratory distress syndrome (ARDS).[1-3] There are more than 300,000 patients who undergo cardiac surgery every year in the United States, as many as 20% will have ARDS.[4] The risk factors include the type of surgery, cardiopulmonary bypass, ischemia-reperfusion injury, transfusion-related acute lung injury and drug toxicity. The mortality rate associated with ARDS is approximately 40% in the general population, but much higher among post-cardiac surgery patients, which may be as high as 80%.[5 6] Moderate to severe ARDS causes the majority of death cases, and the possible therapeutic choices are different in different severity of ARDS. Mild ARDS patients usually need non-invasive treatments, while moderate to severe ARDS patients are more likely in need of more aggressive interventions such as prone positioning, recruitment maneuver, neuromuscular blockage agents, inhaled nitric oxide, high frequency oscillatory ventilation and even extracorporeal membrane oxygenation. It is meaningful to identify patients with moderate to severe ARDS.

Although cardiac surgery with cardiopulmonary bypass (CPB) is considered a highly sterile type of surgery, it can lead to a systemic inflammatory response syndrome (SIRS).[7] The possible causes are the exposure of blood to non-physiological surfaces, ischemia-reperfusion injury due to aortic clamping and extracorporeal circulation,[8] as well as a translocation of endotoxins from gut to the bloodstream after the release of the aortic clamp,[9] which can activate inflammatory cascades similar to those observed in sepsis. Cytokines such as interleukin (IL)-6, IL-8, tumor

1  
2  
3  
4 necrosis factor (TNF)-alpha as well as C-reactive protein (CRP), lipoprotein-binding  
5  
6 protein (LBP) and procalcitonin (PCT) may play an important role in the immune  
7  
8 reaction, while PCT liberation is predominantly depended on the use of CPB.[10]  
9

10  
11 PCT is initially described as an early, sensitive and specific marker for sepsis  
12  
13 associated with bacterial infection.[11] However, it is also increased in clinical  
14  
15 situations without infections such as major surgery, burns, or trauma.[12] Previous  
16  
17 studies suggested that the concentration of serum PCT increased at the end of CPB,  
18  
19 reaching its peak on the first day and then declined rapidly.[7 13] It is also suggested  
20  
21 that significant elevation of PCT level can be observed when complications  
22  
23 presented.[7 14 15] Therefore, we hypothesis that PCT could be a predictor of the  
24  
25 development of ARDS, especially moderate to severe ARDS, in patients undergo  
26  
27 cardiac surgery with CPB. Our aim is to validate that whether patients with different  
28  
29 serum PCT concentration have different incidence of developing moderate to severe  
30  
31 ARDS.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Methods and analysis

### Study design overview

The present study is a prospective, single center, observational cohort study in patients after elective cardiac surgery.

### Study setting and population

The study setting is cardiosurgical intensive care unit (ICU) (20 beds) and cardiosurgery department (118 beds), Fujian Provincial Hospital (2500 beds), Fujian Provincial Clinical College of Fujian Medical University, Fuzhou, China.

All patients admitted to the cardiosurgery department who are programmed for a cardiac surgery under CPB are screened for study eligibility.

Inclusion criteria are:

- 1) Age 18 years and above;
- 2) Programmed cardiac surgery under CPB;
- 3) Be free from active preoperative infection or inflammatory disease (meet all of the following criteria at study entry: leukocyte count  $< 12 \times 10^9/L$ , PCT  $< 0.5$  ng/ml, body temperature  $< 37.5^\circ C$ );
- 4) Able to consent.

Exclusion criteria are:

- 1) History of chronic obstructive pulmonary disease (COPD), asthma or interstitial lung disease (ILD);

- 2) History of lung surgery;
- 3) Pregnant or lactating women;
- 4) Unwillingness of the patient to provide consent;
- 5) Enrolled in another trial.

### **Anesthesia, CPB and perioperative management**

All patients' cardiosurgery undergo with general anesthesia and median sternotomy.

Anticoagulation is obtained by using sodium heparin at a dose of 3 mg/kg for CPB patients. After attaining an activating clotting time (ACT) greater than 480 seconds,

CPB is initiated by using an occlusive roller pump (jostra, Germany) and a membrane oxygenator (affinity7000, American), followed with moderate hypothermia (28°C) and

crystalloid cardioplegic cardiac arrest. Pump flow is about 2.0-2.6 l/min/m<sup>2</sup> during CPB and the mean arterial pressure (MAP) is maintained between 60 and 80 mmHg.

At the end of surgery, protamine is given at a 1:1 ratio for reversal of the heparin effect (to obtain an ACT < 160s). The ventilator is initially set to deliver a tidal

volume around 7-10 ml/kg and a respiratory rate adjusted to maintain an arterial CO<sub>2</sub> pressure (PaCO<sub>2</sub>) between 35 and 40 mmHg during the surgery. Cephazolin is used as

perioperative antibiotic prophylaxis. Patients are monitored postoperatively in the ICU and ventilated until they meet the following criteria:

- 1) Awake and cooperative;
- 2) Adequate recovery of muscle strength;
- 3) Normal tidal volume, normocapnia (end-tidal carbon dioxide 30-45 mmHg),

1  
2  
3  
4 minimum pulse oxygen saturation ( $SpO_2$ )  $\geq$  95% with fraction of inspiration oxygen  
5  
6 ( $FiO_2$ ) 0.5;

7  
8  
9 4) Hemodynamic stability (small dosage of vasopressor support and mean arterial  
10  
11 pressure within 10-15% of baseline);

12  
13  
14 5) No severe arrhythmias;

15  
16 6) No bleeding or indications of re-exploration.

17  
18 Patients' endotracheal tube is removed if they meet the criteria. Patients are  
19  
20 discharged from ICU after successful extubation. In our clinical practice, blood  
21  
22 samples are routinely obtained for test of whole blood routine before and 1 day after  
23  
24 operation, respectively. PCT is also tested before and 1 day after operation.  
25  
26  
27  
28 N-terminal pro-B-type natriuretic peptide (Nt-pro-BNP) and CRP are tested 1 day  
29  
30 after operation. Chest X-ray is routinely obtained before operation, 1 day and 7 days  
31  
32 after operation, respectively. Additional chest X-ray examinations are performed if  
33  
34 patients represent hypoxia due to suspicious infection, pulmonary atelectasis,  
35  
36 pleural effusion or ARDS. Blood gas analysis is tested at least once per day when the  
37  
38 patients are in the ICU. After they are transferred to the routine room, blood gas  
39  
40 analysis is tested when the physicians considered it is necessary, or when patients'  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

### Follow up and data collection

This is an observational study that no intervention is applied. At study entry, data on demographic, history of smoking, history of past illness characteristics, diagnosis and



1  
2  
3  
4 the New York Heart Association (NYHA) functional classification [16] are collected.  
5  
6 Type of surgery, duration of operation, CPB and aortic clamping and net fluid balance  
7  
8 during the operation are recorded. The concentration of serum CRP, Nt-pro-BNP and  
9  
10 PCT level on the first postoperative day are also recorded. Patients are assigned to the  
11  
12 PCT elevated cohort or control cohort according to serum PCT concentration on the  
13  
14 first postoperative day with a cut-off value of 7.0 ng/ml. Daily fluid balance and  
15  
16 highest vasoactive-inotropic score (VIS) are calculated. VIS is calculated as dopamine  
17  
18 dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) + dobutamine dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) + 100  $\times$  epinephrine dose  
19  
20 ( $\mu\text{g}/\text{kg}/\text{min}$ ) + 100  $\times$  norepinephrine dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) + 15  $\times$  milrinone dose  
21  
22 ( $\mu\text{g}/\text{kg}/\text{min}$ ) + 10000  $\times$  vasopressin dose (U/kg/min).[17] Data are collected until the  
23  
24 seventh day after operation. ARDS is diagnosed according to the Berlin definition.[18]  
25  
26 A checklist (Table 1) is used to assess the development of moderate to severe ARDS.  
27  
28 Two physicians make the diagnosis independently. Only the patients who are  
29  
30 diagnosed by both two physicians are considered with moderate to severe ARDS.  
31  
32 Echocardiography or pulmonary artery catheter (PAC) is applied to exclude  
33  
34 hydrostatic edema. Physicians who assess the development of ARDS are unaware of  
35  
36 patients' PCT level.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1 Checklist of ARDS

	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
<b>Timing:</b> Within 1 week of a known clinical insult or new or worsening respiratory symptoms	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>Chest imaging:</b> Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>Origin of edema:</b> Respiratory failure not fully explained by cardiac failure or fluid overload	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>Oxygenation</b>							
<b>Mild:</b> $200 \text{ mm Hg} < \text{PaO}_2/\text{FiO}_2 \leq 300 \text{ mm Hg}$ with PEEP or CPAP $\geq 5 \text{ cm H}_2\text{O}$	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>
<b>Moderate:</b> $100 \text{ mm Hg} < \text{PaO}_2/\text{FiO}_2 \leq 200 \text{ mm Hg}$ with PEEP $\geq 5 \text{ cm H}_2\text{O}$	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>
<b>Severe:</b> $\text{PaO}_2/\text{FiO}_2 \leq 100 \text{ mm Hg}$ with PEEP $\geq 5 \text{ cm H}_2\text{O}$	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>
Does the patient developed ARDS?	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>

Abbreviations: CPAP, continuous positive airway pressure; FiO<sub>2</sub>, fraction of inspired oxygen; PaO<sub>2</sub>, partial pressure of arterial oxygen; PEEP, positive end-expiratory pressure.

### **PCT determination**

Serum PCT levels were measured by a highly sensitive and specific commercially available immunoluminometric assay kit (Vidasbrahms PCT, mini VIDS, Italy) according to the manufacturer's recommendation. Quantitative measurement allowed determination of PCT concentrations ranging from 0.05 to 200 ng/ml.

### **Study endpoints**

The primary endpoint is incidence of moderate to severe ARDS.

Secondary endpoints include:

- 1) The duration of mechanical ventilation;
- 2) The length of ICU stay;
- 3) Complications after surgery.

### **Sample size**

Primarily, we expect the incidence of moderate to severe ARDS is higher in the PCT elevated group than in the control group. Previous investigations showed the overall morbidity of moderate to severe ARDS was around 0.5%-2% of patients underwent cardiac surgery.[1-3] Our pilot study showed that the incidence could be as high as 15% in the patients with elevated PCT level. Using the Power and Sample Size Calculation program, we will need to investigate 64 exposure subjects and 64 control subjects to be able to reject the null hypothesis. The Type I error probability ( $\alpha$ ) with testing this null hypothesis is 0.05 and Type II error probability ( $\beta$ ) is 0.2.

### Statistical analysis

Baseline characteristics will be summarized by univariate analyses. Categorical variables will be presented as numbers and percentages, and analyzed by the  $\chi^2$ -test. Continuous variables will be checked for normal distribution and presented as mean and standard deviation or median and inter-quartile range as appropriate. Comparison of continuous variables will be performed by using Student's t-test for normally distributed variables and the Mann-Whitney U test for non-normally distributed variables. All tests of significance will be at the 5% significance level, and two-sided. Analyses are performed by using SPSS 19.0 (IBM Corporation, New York, USA).

### **Ethical aspects and informed consent**

The study protocol and consent forms were approved on August 7th, 2014 by the Institutional Review Board of Fujian Provincial Hospital. The study was registered on August 8th, 2014 at the ClinicalTrials.org (ChiCTR-OCH-14005076).

After patient's eligibility for the study is confirmed, the study coordinator will be introduced to the family. The surgeon will make sure the family knows the credentials of the study coordinator, and says that this person is going to discuss a research program being conducted, and the patient is qualified to do so. Every relevant aspect of the project will be described. The study coordinator will stop frequently, ask if there are any questions, and request that the family repeat back in their own words what is being discussed, to make sure they understand. The study coordinator will be especially careful to assure the family that they are free to decline consent without consequences and that they can withdraw consent at any time without impact on treatment. Family members will be provided with contact information for the study coordinator, local co-investigator and the local Ethical Committee. Written consent will be obtained in the presence of a witness.

### **Dissemination plan**

Results of the trial will be submitted to international peer reviewed journal. Results will also be presented at national and international conferences relevant to subject fields.

**Authors' contributions**

HC and RGY participated in the design of the study and drafted the manuscript. ZBC participated in the design of the study. All authors edited the manuscript and read and approved the final manuscript.

**Funding statement:**

This work was supported by grants from the National Clinical Key Specialty (2011170). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests**

The authors declare that they have no competing interests.

## References

1. Milot J, Perron J, Lacasse Y, Letourneau L, Cartier PC, Maltais F. Incidence and predictors of ARDS after cardiac surgery. *Chest* 2001;**119**(3):884-8
2. Christenson JT, Aeberhard JM, Badel P, et al. Adult respiratory distress syndrome after cardiac surgery. *Cardiovascular surgery (London, England)* 1996;**4**(1):15-21
3. Kaul TK, Fields BL, Riggins LS, Wyatt DA, Jones CR, Nagle D. Adult respiratory distress syndrome following cardiopulmonary bypass: incidence, prophylaxis and management. *The Journal of cardiovascular surgery* 1998;**39**(6):777-81
4. Stephens RS, Shah AS, Whitman GJ. Lung injury and acute respiratory distress syndrome after cardiac surgery. *The Annals of thoracic surgery* 2013;**95**(3):1122-9 doi: 10.1016/j.athoracsur.2012.10.024[published Online First: Epub Date]].
5. Weissman C. Pulmonary complications after cardiac surgery. *Seminars in cardiothoracic and vascular anesthesia* 2004;**8**(3):185-211
6. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. *The New England journal of medicine* 2005;**353**(16):1685-93 doi: 10.1056/NEJMoa050333[published Online First: Epub Date]].
7. Prat C, Ricart P, Ruyra X, et al. Serum concentrations of procalcitonin after cardiac surgery. *Journal of cardiac surgery* 2008;**23**(6):627-32 doi: 10.1111/j.1540-8191.2008.00658.x[published Online First: Epub Date]].
8. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. *The Journal of thoracic and cardiovascular surgery* 1994;**108**(4):626-35
9. Rocke DA, Gaffin SL, Wells MT, Koen Y, Brock-Utine JG. Endotoxemia associated with cardiopulmonary bypass. *The Journal of thoracic and cardiovascular surgery* 1987;**93**(6):832-7
10. Franke A, Lante W, Fackeldey V, et al. Pro-inflammatory cytokines after different kinds of cardio-thoracic surgical procedures: is what we see what we know? *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery* 2005;**28**(4):569-75 doi: 10.1016/j.ejcts.2005.07.007[published Online First: Epub Date]].
11. Assicot M, Bohuon C, Gendrel D, Raymond J, Carsin H, Guilbaud J. High serum procalcitonin concentrations in patients with sepsis and infection. *The Lancet* 1993;**341**(8844):515-18
12. Reinhart K, Karzai W, Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. *Intensive care medicine* 2000;**26**(9):1193-200
13. Kallel S, Abid M, Jarraya A, et al. [Kinetics, diagnostic and prognostic value of procalcitonin after cardiac surgery]. *Annales de biologie clinique* 2012;**70**(5):567-80 doi: 10.1684/abc.2012.0745[published Online First: Epub Date]].
14. Dorge H, Schondube FA, Dorge P, Seipelt R, Voss M, Messmer BJ. Procalcitonin is a valuable prognostic marker in cardiac surgery but not specific for infection. *The Thoracic and cardiovascular surgeon* 2003;**51**(6):322-6 doi: 10.1055/s-2003-45425[published Online First: Epub Date]].
15. Kallel S, Jmel W, Jarraya A, Abdenadher M, Frikha I, Karouia A. The role of procalcitonin and N-terminal pro-B-type natriuretic peptide in predicting outcome after cardiac surgery.

1  
2  
3 Perfusion 2012;**27**(6):504-11 doi: 10.1177/0267659112454155[published Online First: Epub  
4 Date]].

- 5  
6 16. AHA medical/scientific statement. 1994 revisions to classification of functional capacity and  
7 objective assessment of patients with diseases of the heart. *Circulation* 1994;**90**(1):644-5  
8  
9 17. Gaies MG, Gurney JG, Yen AH, et al. Vasoactive-inotropic score as a predictor of morbidity and  
10 mortality in infants after cardiopulmonary bypass. *Pediatric critical care medicine : a journal*  
11 *of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and*  
12 *Critical Care Societies* 2010;**11**(2):234-8 doi: 10.1097/PCC.0b013e3181b806fc[published  
13 Online First: Epub Date]].  
14  
15 18. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin  
16 Definition. *JAMA : the journal of the American Medical Association* 2012;**307**(23):2526-33 doi:  
17 10.1001/jama.2012.5669[published Online First: Epub Date]].  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 **Procalcitonin as a predictor of moderate to severe acute respiratory**  
5  
6 **distress syndrome (ARDS) after cardiac surgery with**  
7  
8 **cardiopulmonary bypass (CPB): a study protocol for a prospective**  
9  
10 **cohort study**  
11  
12

13 Han Chen, MD; Zhang-Bo Cheng, MD; Rong-Guo Yu, MD\*

14  
15  
16 Surgical Intensive Care Unit, Fujian Provincial Clinical College of Fujian Medical  
17  
18 University, Fujian Provincial Hospital, Fuzhou, Fujian, 350001, PR China (H.C. and  
19  
20 R.G.Y.) and Department of Cardiosurgery, Fujian Provincial Clinical College of  
21  
22 Fujian Medical University, Fujian Cardiovascular Research Institute, Fuzhou, Fujian,  
23  
24 350001, PR China (ZB.C.)  
25  
26  
27  
28  
29  
30

31 \*: Corresponding author  
32

33 Rong-Guo Yu  
34

35  
36 Surgical Intensive Care Unit, Fujian Provincial Clinical College of Fujian Medical  
37  
38 University, Fujian Provincial Hospital  
39

40 Address: 134 Dongjie Street, Gulou district, Fuzhou, 350001, PR China  
41

42 Telephone: +86 0591 88217010  
43

44 Email: [garyyrg@yahoo.com](mailto:garyyrg@yahoo.com)  
45  
46

47 Email of authors:  
48

49 Han Chen: [baojr2@163.com](mailto:baojr2@163.com)  
50  
51

52 Zhang-Bo Cheng: [16016331@qq.com](mailto:16016331@qq.com)  
53  
54

55 Word count: 1707  
56  
57  
58  
59  
60

## Abstract

**Introduction:** Procalcitonin (PCT) is activated during cardiopulmonary bypass (CPB) and may be a predictor of acute respiratory distress syndrome (ARDS). The object is to validate that whether patients with different serum PCT concentration have different incidence of developing moderate to severe ARDS.

**Methods and analysis:** The study is a prospective, single center, observational cohort study. All patients admitted to the cardiosurgery department who are programmed for a cardiac surgery with CPB are screened for study eligibility. All eligible patients will receive operation with CPB. Blood samples are obtained for test of white blood cell (WBC) count, N-terminal pro-B-type natriuretic peptide (Nt-pro-BNP), C-reactive protein (CRP) and procalcitonin (PCT). Patients are assigned to PCT elevated cohort or control cohort according to serum PCT concentration on the first postoperative day with a cut-off value of 7.0 ng/ml. Data will be collected daily for seven days, which including baseline data, perioperative data and outcomes. The primary endpoint is incidence of moderate to severe ARDS, which is diagnosed according to the Berlin definition.

**Ethics and dissemination:** The study was approved by the Institutional Review Board of Fujian Provincial Hospital. Study findings will be disseminated through peer-reviewed publications and conference presentations.

**Trial registration:** Chinese Clinical Trial Registry (ChiCTR-OCH-14005076).

## Introduction

Epidemiological studies have shown that cardiac surgery is a known risk factor for acute respiratory distress syndrome (ARDS).[1-3] There are more than 300,000 patients who undergo cardiac surgery every year in the United States, as many as 20% will have ARDS.[4] The risk factors include the type of surgery, cardiopulmonary bypass, ischemia-reperfusion injury, transfusion-related acute lung injury and drug toxicity. The mortality rate associated with ARDS is approximately 40% in the general population, but much higher among post-cardiac surgery patients, which may be as high as 80%.[5 6] Moderate to severe ARDS causes the majority of death cases, and the possible therapeutic choices are different in different severity of ARDS. Mild ARDS patients usually need non-invasive treatments, while moderate to severe ARDS patients are more likely in need of more aggressive interventions such as prone positioning, recruitment maneuver, neuromuscular blockage agents, inhaled nitric oxide, high frequency oscillatory ventilation and even extracorporeal membrane oxygenation. It is meaningful to identify patients with moderate to severe ARDS.

Although cardiac surgery with cardiopulmonary bypass (CPB) is considered a highly sterile type of surgery, it can lead to a systemic inflammatory response syndrome (SIRS).[7] The possible causes are the exposure of blood to non-physiological surfaces, ischemia-reperfusion injury due to aortic clamping and extracorporeal circulation,[8] as well as a translocation of endotoxins from gut to the bloodstream after the release of the aortic clamp,[9] which can activate inflammatory cascades similar to those observed in sepsis. Cytokines such as interleukin (IL)-6, IL-8, tumor

1  
2  
3  
4 necrosis factor (TNF)-alpha as well as C-reactive protein (CRP), lipoprotein-binding  
5  
6 protein (LBP) and procalcitonin (PCT) may play an important role in the immune  
7  
8 reaction, while PCT liberation is predominantly depended on the use of CPB.[10]  
9

10  
11 PCT is initially described as an early, sensitive and specific marker for sepsis  
12  
13 associated with bacterial infection.[11] However, it is also increased in clinical  
14  
15 situations without infections such as major surgery, burns, or trauma.[12] Previous  
16  
17 studies suggested that the concentration of serum PCT increased at the end of CPB,  
18  
19 reaching its peak on the first day and then declined rapidly.[7 13] It is also suggested  
20  
21 that significant elevation of PCT level can be observed when complications  
22  
23 presented.[7 14 15] Therefore, we hypothesis that PCT could be a predictor of the  
24  
25 development of ARDS, especially moderate to severe ARDS, in patients undergo  
26  
27 cardiac surgery with CPB. Our aim is to validate that whether patients with different  
28  
29 serum PCT concentration have different incidence of developing moderate to severe  
30  
31 ARDS.  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Methods and analysis

### Study design overview

The present study is a prospective, single center, observational cohort study in patients after elective cardiac surgery.

### Study setting and population

The study setting is cardiosurgical intensive care unit (ICU) (20 beds) and cardiosurgery department (118 beds), Fujian Provincial Hospital (2500 beds), Fujian Provincial Clinical College of Fujian Medical University, Fuzhou, China.

All patients admitted to the cardiosurgery department who are programmed for a cardiac surgery under CPB are screened for study eligibility.

Inclusion criteria are:

- 1) Age 18 years and above;
- 2) Programmed cardiac surgery under CPB;
- 3) Be free from active preoperative infection or inflammatory disease (meet all of the following criteria at study entry: leukocyte count  $< 12 \times 10^9/L$ , PCT  $< 0.5$  ng/ml, body temperature  $< 37.5^\circ C$ );
- 4) Able to consent.

Exclusion criteria are:

- 1) History of chronic obstructive pulmonary disease (COPD), asthma or interstitial lung disease (ILD);

- 2) History of lung surgery;
- 3) Pregnant or lactating women;
- 4) Unwillingness of the patient to provide consent;
- 5) Enrolled in another trial.

### **Anesthesia, CPB and perioperative management**

All patients' cardiosurgery undergo with general anesthesia and median sternotomy.

Anticoagulation is obtained by using sodium heparin at a dose of 3 mg/kg for CPB patients. After attaining an activating clotting time (ACT) greater than 480 seconds,

CPB is initiated by using an occlusive roller pump (jostra, Germany) and a membrane oxygenator (affinity7000, American), followed with moderate hypothermia (28°C) and

crystalloid cardioplegic cardiac arrest. Pump flow is about 2.0-2.6 l/min/m<sup>2</sup> during CPB and the mean arterial pressure (MAP) is maintained between 60 and 80 mmHg.

At the end of surgery, protamine is given at a 1:1 ratio for reversal of the heparin effect (to obtain an ACT < 160s). The ventilator is initially set to deliver a tidal

volume around 7-10 ml/kg and a respiratory rate adjusted to maintain an arterial CO<sub>2</sub> pressure (PaCO<sub>2</sub>) between 35 and 40 mmHg during the surgery. Cephazolin is used as

perioperative antibiotic prophylaxis. Patients are monitored postoperatively in the ICU and ventilated until they meet the following criteria:

- 1) Awake and cooperative;
- 2) Adequate recovery of muscle strength;
- 3) Normal tidal volume, normocapnia (end-tidal carbon dioxide 30-45 mmHg),

1  
2  
3  
4 minimum pulse oxygen saturation ( $SpO_2$ )  $\geq 95\%$  with fraction of inspiration oxygen  
5  
6 ( $FiO_2$ ) 0.5;

7  
8  
9 4) Hemodynamic stability (small dosage of vasopressor support and mean arterial  
10  
11 pressure within 10-15% of baseline);

12  
13  
14 5) No severe arrhythmias;

15  
16 6) No bleeding or indications of re-exploration.

17  
18  
19 Patients' endotracheal tube is removed if they meet the criteria. Patients are  
20  
21 discharged from ICU after successful extubation. In our clinical practice, blood  
22  
23 samples are routinely obtained for test of whole blood routine before and 1 day after  
24  
25 operation, respectively. PCT is also tested before and 1 day after operation.  
26  
27  
28 N-terminal pro-B-type natriuretic peptide (Nt-pro-BNP) and CRP are tested 1 day  
29  
30 after operation. Chest X-ray is routinely obtained before operation, 1 day and 7 days  
31  
32 after operation, respectively. Additional chest X-ray examinations are performed if  
33  
34 patients represent hypoxia due to suspicious infection, pulmonary atelectasis,  
35  
36 pleural effusion or ARDS. Blood gas analysis is tested at least once per day when the  
37  
38 patients are in the ICU. After they are transferred to the routine room, blood gas  
39  
40 analysis is tested when the physicians considered it is necessary, or when patients'  
41  
42  $SpO_2$  cannot be maintained greater than 95% with a  $FiO_2$  of 0.5.  
43  
44  
45  
46  
47  
48  
49  
50

### 51 **Follow up and data collection**

52  
53  
54 This is an observational study that no intervention is applied. At study entry, data on  
55  
56 demographic, history of smoking, history of past illness characteristics, diagnosis and  
57  
58  
59  
60

1  
2  
3  
4 the New York Heart Association (NYHA) functional classification [16] are collected.  
5  
6 Type of surgery, duration of operation, CPB and aortic clamping and net fluid balance  
7  
8 during the operation are recorded. The concentration of serum CRP, Nt-pro-BNP and  
9  
10 PCT level on the first postoperative day are also recorded. Patients are assigned to the  
11  
12 PCT elevated cohort or control cohort according to serum PCT concentration on the  
13  
14 first postoperative day with a cut-off value of 7.0 ng/ml. Daily fluid balance and  
15  
16 highest vasoactive-inotropic score (VIS) are calculated. VIS is calculated as dopamine  
17  
18 dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) + dobutamine dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) + 100  $\times$  epinephrine dose  
19  
20 ( $\mu\text{g}/\text{kg}/\text{min}$ ) + 100  $\times$  norepinephrine dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) + 15  $\times$  milrinone dose  
21  
22 ( $\mu\text{g}/\text{kg}/\text{min}$ ) + 10000  $\times$  vasopressin dose (U/kg/min).[17] Data are collected until the  
23  
24 seventh day after operation. ARDS is diagnosed according to the Berlin definition.[18]  
25  
26 A checklist (Table 1) is used to assess the development of moderate to severe ARDS.  
27  
28 Two physicians make the diagnosis independently. Only the patients who are  
29  
30 diagnosed by both two physicians are considered with moderate to severe ARDS.  
31  
32 Echocardiography or pulmonary artery catheter (PAC) is applied to exclude  
33  
34 hydrostatic edema. Physicians who assess the development of ARDS are unaware of  
35  
36 patients' PCT level.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Table 1 Checklist of ARDS

	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
<b>Timing:</b> Within 1 week of a known clinical insult or new or worsening respiratory symptoms	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>Chest imaging:</b> Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>Origin of edema:</b> Respiratory failure not fully explained by cardiac failure or fluid overload	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>Oxygenation</b>							
<b>Mild:</b> $200 \text{ mm Hg} < \text{PaO}_2/\text{FiO}_2 \leq 300 \text{ mm Hg}$ with PEEP or CPAP $\geq 5 \text{ cm H}_2\text{O}$	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>
<b>Moderate:</b> $100 \text{ mm Hg} < \text{PaO}_2/\text{FiO}_2 \leq 200 \text{ mm Hg}$ with PEEP $\geq 5 \text{ cm H}_2\text{O}$	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>
<b>Severe:</b> $\text{PaO}_2/\text{FiO}_2 \leq 100 \text{ mm Hg}$ with PEEP $\geq 5 \text{ cm H}_2\text{O}$	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>
Does the patient developed ARDS?	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>

Abbreviations: CPAP, continuous positive airway pressure; FiO<sub>2</sub>, fraction of inspired oxygen; PaO<sub>2</sub>, partial pressure of arterial oxygen; PEEP, positive end-expiratory pressure.

### **PCT determination**

Serum PCT levels were measured by a highly sensitive and specific commercially available immunoluminometric assay kit (Vidasbrahms PCT, mini VIDS, Italy) according to the manufacturer's recommendation. Quantitative measurement allowed determination of PCT concentrations ranging from 0.05 to 200 ng/ml.

### **Study endpoints**

The primary endpoint is incidence of moderate to severe ARDS.

Secondary endpoints include:

- 1) The duration of mechanical ventilation;
- 2) The length of ICU stay;
- 3) Complications after surgery.

### **Sample size**

Primarily, we expect the incidence of moderate to severe ARDS is higher in the PCT elevated group than in the control group. Previous investigations showed the overall morbidity of moderate to severe ARDS was around 0.5%-2% of patients underwent cardiac surgery.[1-3] Our pilot study showed that the incidence could be as high as 15% in the patients with elevated PCT level. Using the Power and Sample Size Calculation program, we will need to investigate 64 exposure subjects and 64 control subjects to be able to reject the null hypothesis. The Type I error probability ( $\alpha$ ) with testing this null hypothesis is 0.05 and Type II error probability ( $\beta$ ) is 0.2.

## Statistical analysis

Baseline characteristics will be summarized by univariate analyses. Categorical variables will be presented as numbers and percentages, and analyzed by the  $\chi^2$ -test. Continuous variables will be checked for normal distribution and presented as mean and standard deviation or median and inter-quartile range as appropriate. Comparison of continuous variables will be performed by using Student's t-test for normally distributed variables and the Mann-Whitney U test for non-normally distributed variables. All tests of significance will be at the 5% significance level, and two-sided. Analyses are performed by using SPSS 19.0 (IBM Corporation, New York, USA).

### **Ethical aspects and informed consent**

The study protocol and consent forms were approved on ~~October~~August 7th, 2014 by the Institutional Review Board of Fujian Provincial Hospital. The study was registered on ~~October~~August 8th, 2014 at the ClinicalTrials.org (ChiCTR-OCH-14005076).

After patient's eligibility for the study is confirmed, the study coordinator will be introduced to the family. The surgeon will make sure the family knows the credentials of the study coordinator, and says that this person is going to discuss a research program being conducted, and the patient is qualified to do so. Every relevant aspect of the project will be described. The study coordinator will stop frequently, ask if there are any questions, and request that the family repeat back in their own words what is being discussed, to make sure they understand. The study coordinator will be especially careful to assure the family that they are free to decline consent without consequences and that they can withdraw consent at any time without impact on treatment. Family members will be provided with contact information for the study coordinator, local co-investigator and the local Ethical Committee. Written consent will be obtained in the presence of a witness.

### **Dissemination plan**

Results of the trial will be submitted to international peer reviewed journal. Results will also be presented at national and international conferences relevant to subject fields.

**Authors' contributions**

HC and RGY participated in the design of the study and drafted the manuscript. ZBC participated in the design of the study. All authors edited the manuscript and read and approved the final manuscript.

**Funding statement:**

This work was supported by grants from the National Clinical Key Specialty (2011170). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests**

The authors declare that they have no competing interests.

## References

1. Milot J, Perron J, Lacasse Y, Letourneau L, Cartier PC, Maltais F. Incidence and predictors of ARDS after cardiac surgery. *Chest* 2001;**119**(3):884-8
2. Christenson JT, Aeberhard JM, Badel P, et al. Adult respiratory distress syndrome after cardiac surgery. *Cardiovascular surgery (London, England)* 1996;**4**(1):15-21
3. Kaul TK, Fields BL, Riggins LS, Wyatt DA, Jones CR, Nagle D. Adult respiratory distress syndrome following cardiopulmonary bypass: incidence, prophylaxis and management. *The Journal of cardiovascular surgery* 1998;**39**(6):777-81
4. Stephens RS, Shah AS, Whitman GJ. Lung injury and acute respiratory distress syndrome after cardiac surgery. *The Annals of thoracic surgery* 2013;**95**(3):1122-9 doi: 10.1016/j.athoracsur.2012.10.024[published Online First: Epub Date]].
5. Weissman C. Pulmonary complications after cardiac surgery. *Seminars in cardiothoracic and vascular anesthesia* 2004;**8**(3):185-211
6. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. *The New England journal of medicine* 2005;**353**(16):1685-93 doi: 10.1056/NEJMoa050333[published Online First: Epub Date]].
7. Prat C, Ricart P, Ruyra X, et al. Serum concentrations of procalcitonin after cardiac surgery. *Journal of cardiac surgery* 2008;**23**(6):627-32 doi: 10.1111/j.1540-8191.2008.00658.x[published Online First: Epub Date]].
8. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. *The Journal of thoracic and cardiovascular surgery* 1994;**108**(4):626-35
9. Rocke DA, Gaffin SL, Wells MT, Koen Y, Brock-Utine JG. Endotoxemia associated with cardiopulmonary bypass. *The Journal of thoracic and cardiovascular surgery* 1987;**93**(6):832-7
10. Franke A, Lante W, Fackeldey V, et al. Pro-inflammatory cytokines after different kinds of cardio-thoracic surgical procedures: is what we see what we know? *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery* 2005;**28**(4):569-75 doi: 10.1016/j.ejcts.2005.07.007[published Online First: Epub Date]].
11. Assicot M, Bohuon C, Gendrel D, Raymond J, Carsin H, Guilbaud J. High serum procalcitonin concentrations in patients with sepsis and infection. *The Lancet* 1993;**341**(8844):515-18
12. Reinhart K, Karzai W, Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. *Intensive care medicine* 2000;**26**(9):1193-200
13. Kallel S, Abid M, Jarraya A, et al. [Kinetics, diagnostic and prognostic value of procalcitonin after cardiac surgery]. *Annales de biologie clinique* 2012;**70**(5):567-80 doi: 10.1684/abc.2012.0745[published Online First: Epub Date]].
14. Dorge H, Schondube FA, Dorge P, Seipelt R, Voss M, Messmer BJ. Procalcitonin is a valuable prognostic marker in cardiac surgery but not specific for infection. *The Thoracic and cardiovascular surgeon* 2003;**51**(6):322-6 doi: 10.1055/s-2003-45425[published Online First: Epub Date]].
15. Kallel S, Jmel W, Jarraya A, Abdenadher M, Frikha I, Karouia A. The role of procalcitonin and N-terminal pro-B-type natriuretic peptide in predicting outcome after cardiac surgery.

1  
2  
3 Perfusion 2012;**27**(6):504-11 doi: 10.1177/0267659112454155[published Online First: Epub  
4 Date]].

- 5  
6 16. AHA medical/scientific statement. 1994 revisions to classification of functional capacity and  
7 objective assessment of patients with diseases of the heart. *Circulation* 1994;**90**(1):644-5  
8  
9 17. Gaies MG, Gurney JG, Yen AH, et al. Vasoactive-inotropic score as a predictor of morbidity and  
10 mortality in infants after cardiopulmonary bypass. *Pediatric critical care medicine : a journal*  
11 *of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and*  
12 *Critical Care Societies* 2010;**11**(2):234-8 doi: 10.1097/PCC.0b013e3181b806fc[published  
13 Online First: Epub Date]].  
14  
15 18. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin  
16 Definition. *JAMA : the journal of the American Medical Association* 2012;**307**(23):2526-33 doi:  
17 10.1001/jama.2012.5669[published Online First: Epub Date]].  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# BMJ Open

## Procalcitonin as a predictor of moderate to severe acute respiratory distress syndrome after cardiac surgery with cardiopulmonary bypass: a study protocol for a prospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2014-006344.R2
Article Type:	Protocol
Date Submitted by the Author:	13-Oct-2014
Complete List of Authors:	Chen, Han; Fujian Provincial Clinical College of Fujian Medical University, Surgical Intensive Care Unit; Fujian Provincial Hospital, Surgical Intensive Care Unit Cheng, Zhang-Bo; Fujian Provincial Hospital, Department of Cardiosurgery; Fujian Cardiovascular Research Institute, Yu, Rong-Guo; Fujian Provincial Clinical College of Fujian Medical University, Surgical Intensive Care Unit; Fujian Provincial Hospital, Surgical Intensive Care Unit
<b>Primary Subject Heading</b>:	Intensive care
Secondary Subject Heading:	Anaesthesia, Cardiovascular medicine
Keywords:	Adult intensive & critical care < INTENSIVE & CRITICAL CARE, Cardiac surgery < SURGERY, Anaesthesia in cardiology < ANAESTHETICS

SCHOLARONE™  
Manuscripts

only



1  
2  
3  
4 **Procalcitonin as a predictor of moderate to severe acute respiratory**  
5  
6 **distress syndrome after cardiac surgery with cardiopulmonary**  
7  
8  
9 **bypass: a study protocol for a prospective cohort study**

10  
11 Han Chen, MD; Zhang-Bo Cheng, MD; Rong-Guo Yu, MD\*

12  
13 Surgical Intensive Care Unit, Fujian Provincial Clinical College of Fujian Medical  
14  
15 University, Fujian Provincial Hospital, Fuzhou, Fujian, 350001, PR China (H.C. and  
16  
17 R.G.Y.) and Department of Cardiosurgery, Fujian Provincial Clinical College of  
18  
19 Fujian Medical University, Fujian Cardiovascular Research Institute, Fuzhou, Fujian,  
20  
21 350001, PR China (ZB.C.)  
22  
23  
24  
25

26  
27  
28  
29 \*: Corresponding author

30  
31 Rong-Guo Yu

32  
33 Surgical Intensive Care Unit, Fujian Provincial Clinical College of Fujian Medical  
34  
35 University, Fujian Provincial Hospital  
36  
37

38  
39 Address: 134 Dongjie Street, Gulou District, Fuzhou, 350001, PR China

40  
41 Telephone: +86 0591 88217010

42  
43  
44 Email: [garyyrg@yahoo.com](mailto:garyyrg@yahoo.com)

45  
46  
47 Email of authors:

48  
49 Han Chen: [baojr2@163.com](mailto:baojr2@163.com)

50  
51 Zhang-Bo Cheng: [16016331@qq.com](mailto:16016331@qq.com)

52  
53  
54 Word count: 1797

## Abstract

**Introduction:** Procalcitonin (PCT) is activated during cardiopulmonary bypass (CPB) and may be a predictor of acute respiratory distress syndrome (ARDS). The objective of this study is to determine whether patients with different serum PCT concentrations exhibit different rates of developing moderate to severe ARDS.

**Methods and analysis:** This is a prospective, single centre, observational cohort study. All patients admitted to the cardiosurgery department for cardiac surgery with CPB were screened for study eligibility. All eligible patients received a CPB procedure. Blood samples were obtained to determine white blood cell (WBC) counts as well as N-terminal pro-B-type natriuretic peptide (Nt-pro-BNP), C-reactive protein (CRP) and procalcitonin (PCT) levels. Patients were assigned to the PCT elevated cohort or the control cohort based on serum PCT concentrations on the first postoperative day with a cut-off value of 7.0 ng/ml. Data, including baseline, perioperative and outcome data, were collected daily for seven days. The primary endpoint was the incidence of moderate to severe ARDS, which was diagnosed according to the Berlin definition.

**Ethics and dissemination:** The study was approved by the Institutional Review Board of Fujian Provincial Hospital. Study findings are disseminated through peer-reviewed publications and conference presentations.

**Study registration:** Chinese Clinical Trial Registry (ChiCTR-OCH-14005076).

## Introduction

Epidemiological studies have demonstrated that cardiac surgery is a known risk factor for acute respiratory distress syndrome (ARDS).[1-3] Over 300,000 patients undergo cardiac surgery every year in the United States, and up to 20% will experience ARDS.[4] The risk factors include the type of surgery, cardiopulmonary bypass, ischemia-reperfusion injury, transfusion-related acute lung injury and drug toxicity. The mortality rate associated with ARDS is approximately 40% in the general population; however, this rate is considerably higher (up to 80%) among post-cardiac surgery patients. [5 6] Moderate to severe ARDS causes the majority of deaths associated with this syndrome, and the possible therapeutic choices differ for the varying severities of ARDS. Mild ARDS patients typically only require non-invasive treatments, whereas moderate to severe ARDS patients are more likely to require more aggressive interventions, including prone positioning, recruitment manoeuvres, neuromuscular blockage agents, inhaled nitric oxide, high frequency oscillatory ventilation and even extracorporeal membrane oxygenation. Thus, the identification of patients with moderate to severe ARDS is clinically meaningful.

Although cardiac surgery with cardiopulmonary bypass (CPB) is considered a highly sterile type of surgery, it can lead to a systemic inflammatory response syndrome (SIRS).[7] The possible causes of SIRS include the exposure of blood to non-physiological surfaces, ischemia-reperfusion injury due to aortic clamping and extracorporeal circulation.[8] In addition, the translocation of gut endotoxins to the bloodstream after the release of the aortic clamp is another potential cause[9] that can

1  
2  
3  
4 activate inflammatory cascades similar to those observed in sepsis. Cytokines, such as  
5  
6 interleukin (IL)-6, IL-8, tumour necrosis factor (TNF)-alpha, and C-reactive protein  
7  
8 (CRP), lipoprotein-binding protein (LBP) and procalcitonin (PCT) potentially play  
9  
10 important roles in immune reactions, whereas PCT liberation is predominantly  
11  
12 dependent upon the use of CPB.[10]  
13

14  
15  
16 PCT is initially described as an early, sensitive and specific marker for sepsis  
17  
18 associated with bacterial infection.[11] However, PCT levels are also increased in  
19  
20 clinical situations not associated with infections, including major surgery, burns, or  
21  
22 trauma.[12] Previous studies suggested that serum PCT concentrations increase at the  
23  
24 end of CPB, peaking on the first day and then rapidly declining.[7 13] Data have  
25  
26 suggested that significant increases in PCT levels are observed when complications  
27  
28 present.[7 14 15] Therefore, we hypothesis that PCT could serve as a predictor of the  
29  
30 development of ARDS, especially moderate to severe ARDS, in patients undergoing  
31  
32 cardiac surgery with CPB. Our aim is to determine whether patients with different  
33  
34 serum PCT concentrations exhibit different rates of developing moderate to severe  
35  
36 ARDS.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Methods and analysis

### Study design overview

The present study is a prospective, single centre, observational cohort study involving patients undergoing elective cardiac surgery.

### Study setting and population

The study setting is a cardiosurgical intensive care unit (ICU) (20 beds) and cardiosurgery department (118 beds) at Fujian Provincial Hospital (2500 beds), Fujian Provincial Clinical College of Fujian Medical University, Fuzhou, China.

All patients admitted to the cardiosurgery department for a cardiac surgery involving CPB were screened for study eligibility.

The following inclusion criteria were used:

- 1) Patients are 18 years of age and older;
- 2) Patients underwent cardiac surgery involving CPB;
- 3) Patients are free from active preoperative infection or inflammatory disease (all of the following criteria were achieved at study entry: leukocyte count  $< 12 \times 10^9/L$ , PCT  $< 0.5$  ng/ml, body temperature  $< 37.5^\circ C$ );
- 4) Patients are capable of providing consent.

The following exclusion criteria were used:

- 1) History of chronic obstructive pulmonary disease (COPD), asthma or interstitial lung disease (ILD);

- 2) History of lung surgery;
- 3) Pregnant or lactating women;
- 4) Unwilling to provide consent;
- 5) Enrolled in another trial.

### **Anaesthesia, CPB and perioperative management**

All patients undergo cardiosurgery with general anaesthesia via median sternotomy.

Anticoagulation is promoted in CPB patients via the administration of 3 mg/kg sodium heparin. After attaining an activating clotting time (ACT) greater than 480 seconds,

CPB is initiated by using an occlusive roller pump (Jostra, Germany) and a membrane

oxygenator (Affinity7000, American) followed by moderate hypothermia (28°C) and

crystalloid cardioplegic cardiac arrest. The pump flow is approximately 2.0-2.6

l/min/m<sup>2</sup> during CPB. The mean arterial pressure (MAP) is maintained at 60-80

mmHg. At the end of surgery, protamine is administered at a 1:1 ratio to reverse the

heparin effect (to obtain an ACT < 160 s). The ventilator is initially set to deliver a

tidal volume approximately 7-10 ml/kg, and the respiratory rate is adjusted to

maintain an arterial CO<sub>2</sub> pressure (PaCO<sub>2</sub>) of 35-40 mmHg during the surgery.

Cephazolin is administered as perioperative antibiotic prophylaxis. Patients are

monitored postoperatively in the ICU and receive ventilation until the following

criteria are met:

- 1) Awake and cooperative;
- 2) Adequate recovery of muscle strength;

- 3) Normal tidal volume, normocapnia (end-tidal carbon dioxide 30-45 mmHg), and minimum pulse oxygen saturation ( $SpO_2$ )  $\geq 95\%$  with a fraction of inspiration oxygen ( $FiO_2$ ) of 0.5;
- 4) Hemodynamic stability (small dosage of vasopressor support and mean arterial pressure within 10-15% of baseline);
- 5) No severe arrhythmias;
- 6) No bleeding or indications of re-exploration.

The patient's endotracheal tube is removed if he/she achieves the criteria. Patients are discharged from the ICU after successful extubation. In our clinical practice, blood samples are routinely obtained for whole blood assessment prior to and 1 day after the operation. PCT is also assessed prior to and 1 day after the operation. N-terminal pro-B-type natriuretic peptide (Nt-pro-BNP) and CRP levels are assessed 1 day after the operation. A chest X-ray is routinely obtained prior to the operation as well as 1 and 7 days after the operation. Additional chest X-ray examinations are performed if patients exhibit hypoxia due to suspicious infection, pulmonary atelectasis, pleural effusion or ARDS. A blood gas analysis is performed at least once daily when the patients are in the ICU. After they are transferred to a normal room, a blood gas analysis is performed when deemed necessary by the physicians or when patients'  $SpO_2$  cannot be maintained at a level greater than 95% with a  $FiO_2$  of 0.5.

#### **Follow-up and data collection**

This is an observational study wherein no intervention is applied. At study entry, data

1  
2  
3  
4 regarding patient demographics, history of smoking, history of past illness patient  
5  
6 characteristics, diagnosis and the New York Heart Association (NYHA) functional  
7  
8 classification [16] are collected. The type of surgery, duration of operation, CPB and  
9  
10 aortic clamping and net fluid balance during the operation are recorded. Serum CRP,  
11  
12 Nt-pro-BNP and PCT concentrations are also recorded on the first postoperative day.  
13  
14 Patients are assigned to the PCT elevated cohort or control cohort based on serum  
15  
16 PCT concentrations on the first postoperative day using a cut-off value of 7.0 ng/ml.  
17  
18  
19  
20  
21 Daily fluid balance and highest vasoactive-inotropic score (VIS) are calculated. VIS is  
22  
23 calculated as dopamine dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) + dobutamine dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) +  $100 \times$   
24  
25 epinephrine dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) +  $100 \times$  norepinephrine dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) +  $15 \times$   
26  
27 milrinone dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) +  $10000 \times$  vasopressin dose (U/kg/min).[17] Data are  
28  
29 collected until the seventh day after the operation. ARDS is diagnosed according to  
30  
31 the Berlin definition. [18] A checklist (Table 1) is used to assess the development of  
32  
33 moderate to severe ARDS. Two physicians make the diagnosis independently. Only  
34  
35 patients diagnosed with moderate to severe ARDS by both physicians are considered.  
36  
37  
38  
39  
40 Echocardiography or pulmonary artery catheter (PAC) is applied to exclude  
41  
42 hydrostatic oedema. Physicians who assess the development of ARDS are unaware of  
43  
44 the patient's PCT level.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



Table 1 ARDS Checklist

	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
<b>Timing:</b> Within 1 week of a known clinical insult or new or worsening respiratory symptoms	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>Chest imaging:</b> Bilateral opacities not fully explained by effusions, lobar/lung collapse or nodules	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>Origin of oedema:</b> Respiratory failure not fully explained by cardiac failure or fluid overload	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>Oxygenation</b>							
<b>Mild:</b> 200 mm Hg < PaO <sub>2</sub> /FiO <sub>2</sub> ≤ 300 mm Hg with PEEP or CPAP ≥ 5 cm H <sub>2</sub> O	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>
<b>Moderate:</b> 100 mm Hg < PaO <sub>2</sub> /FiO <sub>2</sub> ≤ 200 mm Hg with PEEP ≥ 5 cm H <sub>2</sub> O	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>
<b>Severe:</b> PaO <sub>2</sub> /FiO <sub>2</sub> ≤ 100 mm Hg with PEEP ≥ 5 cm H <sub>2</sub> O	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>
Has the patient developed ARDS?	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>

Abbreviations: CPAP, continuous positive airway pressure; FiO<sub>2</sub>, fraction of inspired oxygen; PaO<sub>2</sub>, partial pressure of arterial oxygen; PEEP, positive end-expiratory pressure.

### **PCT determination**

Serum PCT levels were measured using a highly sensitive and specific commercially available immunoluminometric assay kit (Vidasbrahms PCT, mini VIDS, Italy) according to the manufacturer's recommendation. Quantitative measurement allowed the determination of PCT concentrations ranging from 0.05 to 200 ng/ml.

### **Study endpoints**

The primary endpoint is the incidence of moderate to severe ARDS.

The secondary endpoints include the following:

- 1) The duration of mechanical ventilation;
- 2) The length of ICU stay;
- 3) Complications after surgery.

### **Sample size**

Primarily, we expect the incidence of moderate to severe ARDS to be increased in the PCT elevated group compared with the control group. Previous investigations indicate the overall morbidity of moderate to severe ARDS was approximately 0.5%-2% of patients undergoing cardiac surgery.[1-3] Our pilot study revealed that the incidence could be as high as 15% in patients with elevated PCT levels. Using the Power and Sample Size Calculation program, 64 exposure subjects and 64 control subjects must be investigated to be able to reject the null hypothesis. The type I error probability ( $\alpha$ ) for testing our null hypothesis is 0.05, and the type II error probability ( $\beta$ ) is 0.2.

### Statistical analysis

Baseline characteristics were summarised using univariate analyses. Categorical variables are presented as numbers and percentages and analysed using the  $\chi^2$ -test. Continuous variables are assessed for normal distribution and presented as means and standard deviations or medians and inter-quartile ranges as appropriate. Continuous variables are compared using the Student's t-test for normally distributed variables and the Mann-Whitney U test for non-normally distributed variables. All tests of significance were two sided and conducted at the 5% significance level. Subgroup analysis was performed to illustrate the effects of different types of surgery. Analyses are performed using SPSS 19.0 (IBM Corporation, New York, USA).

### **Ethical aspects and informed consent**

The study protocol and consent forms were approved on August 7th, 2014 by the Institutional Review Board of Fujian Provincial Hospital. The study was registered on August 8th, 2014 at ClinicalTrials.org (ChiCTR-OCH-14005076).

After patient eligibility for the study is confirmed, the study coordinator is introduced to the family. The surgeon ensures that the family is aware of the study coordinator's credentials and indicates that this individual will discuss the research program being conducted and that the patient is qualified to participate. Every relevant aspect of the project is described. The study coordinator frequently pauses to ask if there are any questions and requests that the family repeat is the topic being discussed in their own words to ensure that they understand. The study coordinator is especially careful to assure the family that they are free to decline consent without consequences and that they can withdraw consent at any time without impacting treatment. Family members are provided contact information for the study coordinator, local co-investigator and the local Ethical Committee. Written consent is obtained in the presence of a witness.

### **Dissemination plan**

The study results will be submitted to an international peer reviewed journal. Results will also be presented at national and international conferences relevant to the subject fields. We will also consider disseminating the results to the participants.

**Authors' contributions**

HC and RGY participated in the study design and drafted the manuscript. ZBC participated in the study design. All authors edited the manuscript and read and approved the final manuscript.

**Funding statement:**

This work was supported by grants from the National Clinical Key Specialty (2011170). The funders had no role in study design, data collection and analysis, decision to publish or manuscript preparation.

**Competing interests**

The authors declare that they have no competing interests.

## References

1. Milot J, Perron J, Lacasse Y, Letourneau L, Cartier PC, Maltais F. Incidence and predictors of ARDS after cardiac surgery. *Chest* 2001;**119**(3):884-8
2. Christenson JT, Aeberhard JM, Badel P, et al. Adult respiratory distress syndrome after cardiac surgery. *Cardiovascular surgery (London, England)* 1996;**4**(1):15-21
3. Kaul TK, Fields BL, Riggins LS, Wyatt DA, Jones CR, Nagle D. Adult respiratory distress syndrome following cardiopulmonary bypass: incidence, prophylaxis and management. *The Journal of cardiovascular surgery* 1998;**39**(6):777-81
4. Stephens RS, Shah AS, Whitman GJ. Lung injury and acute respiratory distress syndrome after cardiac surgery. *The Annals of thoracic surgery* 2013;**95**(3):1122-9 doi: 10.1016/j.athoracsur.2012.10.024[published Online First: Epub Date]].
5. Weissman C. Pulmonary complications after cardiac surgery. *Seminars in cardiothoracic and vascular anesthesia* 2004;**8**(3):185-211
6. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. *The New England journal of medicine* 2005;**353**(16):1685-93 doi: 10.1056/NEJMoa050333[published Online First: Epub Date]].
7. Prat C, Ricart P, Ruyra X, et al. Serum concentrations of procalcitonin after cardiac surgery. *Journal of cardiac surgery* 2008;**23**(6):627-32 doi: 10.1111/j.1540-8191.2008.00658.x[published Online First: Epub Date]].
8. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. *The Journal of thoracic and cardiovascular surgery* 1994;**108**(4):626-35
9. Rocke DA, Gaffin SL, Wells MT, Koen Y, Brock-Utine JG. Endotoxemia associated with cardiopulmonary bypass. *The Journal of thoracic and cardiovascular surgery* 1987;**93**(6):832-7
10. Franke A, Lante W, Fackeldey V, et al. Pro-inflammatory cytokines after different kinds of cardio-thoracic surgical procedures: is what we see what we know? *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery* 2005;**28**(4):569-75 doi: 10.1016/j.ejcts.2005.07.007[published Online First: Epub Date]].
11. Assicot M, Bohuon C, Gendrel D, Raymond J, Carsin H, Guilbaud J. High serum procalcitonin concentrations in patients with sepsis and infection. *The Lancet* 1993;**341**(8844):515-18
12. Reinhart K, Karzai W, Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. *Intensive care medicine* 2000;**26**(9):1193-200
13. Kallel S, Abid M, Jarraya A, et al. [Kinetics, diagnostic and prognostic value of procalcitonin after cardiac surgery]. *Annales de biologieclinique* 2012;**70**(5):567-80 doi: 10.1684/abc.2012.0745[published Online First: Epub Date]].
14. Dorge H, Schondube FA, Dorge P, Seipelt R, Voss M, Messmer BJ. Procalcitonin is a valuable prognostic marker in cardiac surgery but not specific for infection. *The Thoracic and cardiovascular surgeon* 2003;**51**(6):322-6 doi: 10.1055/s-2003-45425[published Online First: Epub Date]].
15. Kallel S, Jmel W, Jarraya A, Abdenadher M, Frikha I, Karouia A. The role of procalcitonin and N-terminal pro-B-type natriuretic peptide in predicting outcome after cardiac surgery.

1  
2  
3 Perfusion 2012;**27**(6):504-11 doi: 10.1177/0267659112454155[published Online First: Epub  
4 Date]].

- 5  
6 16. AHA medical/scientific statement. 1994 revisions to classification of functional capacity and  
7 objective assessment of patients with diseases of the heart. *Circulation* 1994;**90**(1):644-5
- 8  
9 17. Gaies MG, Gurney JG, Yen AH, et al. Vasoactive-inotropic score as a predictor of morbidity and  
10 mortality in infants after cardiopulmonary bypass. *Pediatric critical care medicine : a journal*  
11 *of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and*  
12 *Critical Care Societies* 2010;**11**(2):234-8 doi: 10.1097/PCC.0b013e3181b806fc[published  
13 Online First: Epub Date]].
- 14  
15 18. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin  
16 Definition. *JAMA : the journal of the American Medical Association* 2012;**307**(23):2526-33 doi:  
17 10.1001/jama.2012.5669[published Online First: Epub Date]].
- 18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7 **Procalcitonin as a predictor of moderate to severe acute respiratory**  
8 **distress syndrome ~~\_(ARDS)~~ after cardiac surgery with**  
9 **cardiopulmonary bypass ~~(CPB)~~: a study protocol for a prospective**  
10 **cohort study**  
11  
12  
13  
14

15 Han Chen, MD; Zhang-Bo Cheng, MD; Rong-Guo Yu, MD\*

16  
17 Surgical Intensive Care Unit, Fujian Provincial Clinical College of Fujian Medical  
18 University, Fujian Provincial Hospital, Fuzhou, Fujian, 350001, PR China (H.C. and  
19 R.G.Y.) and Department of Cardiosurgery, Fujian Provincial Clinical College of  
20 Fujian Medical University, Fujian Cardiovascular Research Institute, Fuzhou, Fujian,  
21 350001, PR China (ZB.C.)  
22  
23  
24  
25  
26  
27  
28  
29  
30

31 \*: Corresponding author

32 Rong-Guo Yu

33  
34 Surgical Intensive Care Unit, Fujian Provincial Clinical College of Fujian Medical  
35 University, Fujian Provincial Hospital

36  
37 Address: 134 Dongjie Street, Gulou ~~district~~District, Fuzhou, 350001, PR China

38  
39 Telephone: +86 0591 88217010

40  
41 Email: [garyyrg@yahoo.com](mailto:garyyrg@yahoo.com)

42  
43 Email of authors:

44  
45 Han Chen: [baojr2@163.com](mailto:baojr2@163.com)

46  
47 Zhang-Bo Cheng: [16016331@qq.com](mailto:16016331@qq.com)

48  
49 Word count: ~~1800~~1797  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## Abstract

**Introduction:** Procalcitonin (PCT) is activated during cardiopulmonary bypass (CPB) and may be a predictor of acute respiratory distress syndrome (ARDS). The objective of this study is to ~~validate that~~ determine whether patients with different serum PCT concentrations ~~have exhibit~~ different incidence rates of developing moderate to severe ARDS.

**Methods and analysis:** ~~The study~~ This is a prospective, single center centre, observational cohort study. All patients admitted to the cardiosurgery department ~~who are programmed~~ for a cardiac surgery with CPB ~~are~~ were screened for study eligibility. All eligible patients ~~will receive operation with~~ received a CPB procedure. Blood samples ~~are were~~ obtained ~~for test of to~~ determine white blood cell (WBC) counts as well as N-terminal pro-B-type natriuretic peptide (Nt-pro-BNP), C-reactive protein (CRP) and procalcitonin (PCT) levels. Patients ~~are~~ were assigned to the PCT elevated cohort or the control cohort ~~according to~~ based on serum PCT concentrations on the first postoperative day with a cut-off value of 7.0 ng/ml. Data, including baseline, perioperative and outcome data, ~~will be~~ were collected daily for seven days, ~~which including baseline data, perioperative data and outcomes~~. The primary endpoint ~~is was the~~ incidence of moderate to severe ARDS, which ~~is was~~ diagnosed according to the Berlin definition.

**Ethics and dissemination:** The study was approved by the Institutional Review Board of Fujian Provincial Hospital. Study findings ~~will be~~ are disseminated through peer-reviewed publications and conference presentations.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Study registration:** Chinese Clinical Trial Registry (ChiCTR-OCH-14005076).

Formatted: Highlight

For peer review only

## Introduction

Epidemiological studies have ~~shown~~ demonstrated that cardiac surgery is a known risk factor for acute respiratory distress syndrome (ARDS).[1-3] ~~There are more than~~ Over 300,000 patients ~~who~~ undergo cardiac surgery every year in the United States, ~~as many as~~ and up to 20% will ~~have~~ experience ARDS.[4] The risk factors include the type of surgery, cardiopulmonary bypass, ischemia-reperfusion injury, transfusion-related acute lung injury and drug toxicity. The mortality rate associated with ARDS is approximately 40% in the general population; ~~however, but much~~ this rate is considerably higher (up to 80%) among post-cardiac surgery patients, ~~which may be as high as 80%.~~ [5 6] Moderate to severe ARDS causes the majority of ~~death~~ deaths associated with this syndrome ~~eases~~, and the possible therapeutic choices ~~are~~ different ~~differ in~~ for the different severity ~~varying severities~~ of ARDS. Mild ARDS patients ~~usually need~~ typically only require non-invasive treatments, ~~while~~ whereas moderate to severe ARDS patients are more likely ~~in need of~~ to require more aggressive interventions, ~~such as~~ including prone positioning, recruitment ~~maneuver~~ manoeuvres, neuromuscular blockage agents, inhaled nitric oxide, high frequency oscillatory ventilation and even extracorporeal membrane oxygenation. ~~It~~ Thus, the identification of ~~is~~ meaningful to identify patients with moderate to severe ARDS is clinically meaningful.

Although cardiac surgery with cardiopulmonary bypass (CPB) is considered a highly sterile type of surgery, it can lead to a systemic inflammatory response syndrome (SIRS).[7] The possible causes ~~are~~ of SIRS include the exposure of blood to

1  
2  
3  
4  
5  
6  
7 non-physiological surfaces, ischemia-reperfusion injury due to aortic clamping and  
8 extracorporeal circulation.<sup>[8]</sup> ~~as well as~~ In addition, the a translocation of gut  
9 endotoxins ~~from gut~~ to the bloodstream after the release of the aortic clamp is another  
10 potential cause.<sup>[9]</sup> ~~which that~~ can activate inflammatory cascades similar to those  
11 observed in sepsis. Cytokines, such as interleukin (IL)-6, IL-8, ~~tumor~~ tumour necrosis  
12 factor (TNF)-alpha, ~~as well as~~ and C-reactive protein (CRP), lipoprotein-binding  
13 protein (LBP) and procalcitonin (PCT) may potentially play ~~an~~ important roles in the  
14 immune reactions, ~~while whereas~~ PCT liberation is predominantly depended  
15 on dependent upon the use of CPB.<sup>[10]</sup>

16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27 PCT is initially described as an early, sensitive and specific marker for sepsis  
28 associated with bacterial infection.<sup>[11]</sup> However, ~~it is~~ PCT levels are also increased in  
29 clinical situations ~~without not associated with~~ infections, ~~such as including~~ major  
30 surgery, burns, or trauma.<sup>[12]</sup> Previous studies suggested that ~~the concentration of~~  
31 serum PCT concentrations increased ~~at the end of CPB, reaching its peak~~ peaking on  
32 the first day and then ~~declined~~ rapidly declining.<sup>[7 13]</sup> ~~It is also~~ Data have suggested  
33 that significant ~~elevation of~~ increases in PCT levels ~~can be~~ are observed when  
34 complications presented.<sup>[7 14 15]</sup> Therefore, we hypothesis that PCT could ~~be serve~~  
35 as a predictor of the development of ARDS, especially moderate to severe ARDS, in  
36 patients ~~undergo~~ undergoing cardiac surgery with CPB. Our aim is to validate  
37 that determine whether patients with different serum PCT concentrations ~~have exhibit~~  
38 different incidence rates of developing moderate to severe ARDS.

## Methods and analysis

### Study design overview

The present study is a prospective, single ~~center~~centre, observational cohort study ~~in~~ involving patients ~~after undergoing~~ elective cardiac surgery.

### Study setting and population

The study setting is ~~a~~ cardiosurgical intensive care unit (ICU) (20 beds) and cardiosurgery department (118 beds) ~~at~~ Fujian Provincial Hospital (2500 beds), Fujian Provincial Clinical College of Fujian Medical University, Fuzhou, China.

All patients admitted to the cardiosurgery department ~~who are programmed~~ for a cardiac surgery ~~under involving~~ CPB ~~are were~~ screened for study eligibility.

~~Inclusion~~ ~~The following inclusion~~ criteria ~~are were~~ used:

- 1) ~~Age~~ Patients are 18 years ~~of age~~ and ~~above~~older;
- 2) ~~Programmed~~ Patients underwent cardiac surgery ~~under involving~~ CPB;
- 3) ~~Be~~ Patients are free from active preoperative infection or inflammatory disease (~~meet~~ all of the following criteria ~~were achieved~~ at study entry: leukocyte count <  $12 \times 10^9/L$ , PCT < 0.5 ng/ml, body temperature < 37.5°C);
- 4) ~~Able to~~ Patients are capable of providing consent.

~~Exclusion~~ ~~The following exclusion~~ criteria ~~are were~~ used:

- 1) History of chronic obstructive pulmonary disease (COPD), asthma or interstitial lung disease (ILD);

- 2) History of lung surgery;
- 3) Pregnant or lactating women;
- 4) ~~Unwillingness of the patient~~ Unwilling to provide consent;
- 5) Enrolled in another trial.

### ~~Anesthesia~~ Anaesthesia, CPB and perioperative management

All patients' ~~cardiosurgery~~ undergo cardiosurgery with general ~~anesthesia~~ anaesthesia and ~~via~~ median sternotomy. Anticoagulation is ~~obtained by using~~ promoted in CPB patients via the administration of sodium heparin at a dose of 3 mg/kg sodium heparin for CPB patients. After attaining an activating clotting time (ACT) greater than 480 seconds, CPB is initiated by using an occlusive roller pump (~~jostra~~ Jostra, Germany) and a membrane oxygenator (~~affinity7000~~ Affinity7000, American); followed ~~with~~ by moderate hypothermia (28°C) and crystalloid cardioplegic cardiac arrest. ~~Pump~~ The pump flow is ~~about 2~~ approximately 2.0-2.6 l/min/m<sup>2</sup> during CPB, ~~and the~~ The mean arterial pressure (MAP) is maintained ~~between~~ at 60- and 80 mmHg. At the end of surgery, protamine is ~~given~~ administered at a 1:1 ratio ~~for reversal of~~ to reverse the heparin effect (to obtain an ACT < ~~160s~~ 160 s). The ventilator is initially set to deliver a tidal volume ~~around 7~~ approximately 7-10 ml/kg, and ~~a the~~ the respiratory rate is adjusted to maintain an arterial CO<sub>2</sub> pressure (PaCO<sub>2</sub>) ~~between of 35 and 40~~ mmHg during the surgery. Cephazolin is ~~used~~ administered as perioperative antibiotic prophylaxis. Patients are monitored postoperatively in the ICU and ~~ventilated~~ receive ventilation until ~~they meet~~ the following criteria are met:

- 1) Awake and cooperative;
- 2) Adequate recovery of muscle strength;
- 3) Normal tidal volume, normocapnia (end-tidal carbon dioxide 30-45 mmHg), and minimum pulse oxygen saturation (SpO<sub>2</sub>) ≥ 95% with a fraction of inspiration oxygen (FiO<sub>2</sub>) of 0.5;
- 4) Hemodynamic stability (small dosage of vasopressor support and mean arterial pressure within 10-15% of baseline);
- 5) No severe arrhythmias;
- 6) No bleeding or indications of re-exploration.

~~Patients<sup>2</sup>~~ The patient's endotracheal tube is removed if ~~they~~ he/she ~~meet~~ achieves the criteria. Patients are discharged from the ICU after successful extubation. In our clinical practice, blood samples are routinely obtained for ~~test of~~ whole blood routine ~~assessment~~ before ~~prior to~~ and 1 day after the operation, ~~respectively~~. PCT is also ~~tested~~ assessed ~~before~~ prior to and 1 day after the operation. N-terminal pro-B-type natriuretic peptide (Nt-pro-BNP) and CRP levels are ~~tested~~ assessed 1 day after the operation. ~~Chest~~ A chest X-ray is routinely obtained ~~before~~ prior to ~~the~~ operation, ~~as~~ well as 1 ~~day~~ and 7 days after the operation, ~~respectively~~. Additional chest X-ray examinations are performed if patients ~~represent~~ exhibit hypoxia due to suspicious infection, pulmonary atelectasis, pleural effusion or ARDS. ~~Blood~~ A blood gas analysis is ~~tested~~ performed at least once ~~per day~~ daily when the patients are in the ICU. After they are transferred to ~~the~~ a ~~routin~~ normal room, a blood gas analysis is ~~tested~~ performed when deemed necessary by the physicians ~~considered it is necessary~~.

1  
2  
3  
4  
5  
6  
7 or when patients' SpO<sub>2</sub> cannot be maintained [at a level](#) greater than 95% with a FiO<sub>2</sub>  
8  
9 of 0.5.

### 10 11 12 13 **Follow-up and data collection**

14  
15 This is an observational study ~~that wherein~~ no intervention is applied. At study entry,  
16 data ~~on regarding patient~~ demographics, history of smoking, history of past illness  
17 [patient](#) characteristics, diagnosis and the New York Heart Association (NYHA)  
18 functional classification [16] are collected. ~~Type~~ [The type](#) of surgery, duration of  
19 operation, CPB and aortic clamping and net fluid balance during the operation are  
20 recorded. ~~The concentration of s~~ Serum CRP, Nt-pro-BNP and PCT [level](#)  
21 [concentrations on the first postoperative day](#) are also recorded [on the first](#)  
22 [postoperative day](#). Patients are assigned to the PCT elevated cohort or control cohort  
23 ~~according to~~ [based on](#) serum PCT concentrations [on the first postoperative day](#) ~~with~~  
24 [using](#) a cut-off value of 7.0 ng/ml. Daily fluid balance and highest  
25 vasoactive-inotropic score (VIS) are calculated. VIS is calculated as dopamine dose  
26 ( $\mu\text{g}/\text{kg}/\text{min}$ ) + dobutamine dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) + 100  $\times$  epinephrine dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) +  
27 100  $\times$  norepinephrine dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) + 15  $\times$  milrinone dose ( $\mu\text{g}/\text{kg}/\text{min}$ ) + 10000  $\times$   
28 vasopressin dose (U/kg/min).[17] Data are collected until the seventh day after [the](#)  
29 operation. ARDS is diagnosed according to the Berlin definition.[18] A checklist  
30 (Table 1) is used to assess the development of moderate to severe ARDS. Two  
31 physicians make the diagnosis independently. Only ~~the patients who are~~ diagnosed  
32 [with moderate to severe ARDS](#) by both ~~two~~ physicians are considered ~~with moderate~~  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4  
5  
6  
7 ~~to severe ARDS~~. Echocardiography or pulmonary artery catheter (PAC) is applied to  
8  
9 exclude hydrostatic ~~edema~~oedema. Physicians who assess the development of ARDS  
10  
11 are unaware of ~~the~~ patient's<sup>2</sup> PCT level.  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1 [Checklist of ARDS Checklist](#)

	Day 1	Day 2	Day 3	Day 4	Day 5	Day 6	Day 7
<b>Timing:</b> Within 1 week of a known clinical insult or new or worsening respiratory symptoms	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>Chest imaging:</b> Bilateral opacities not fully explained by effusions, lobar/lung collapse, or nodules	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>Origin of oedema:</b> Respiratory failure not fully explained by cardiac failure or fluid overload	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>Oxygenation</b>							
<b>Mild:</b> 200 mm Hg < PaO <sub>2</sub> /FiO <sub>2</sub> ≤ 300 mm Hg with PEEP or CPAP ≥ 5 cm H <sub>2</sub> O	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>
<b>Moderate:</b> 100 mm Hg < PaO <sub>2</sub> /FiO <sub>2</sub> ≤ 200 mm Hg with PEEP ≥ 5 cm H <sub>2</sub> O	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>
<b>Severe:</b> PaO <sub>2</sub> /FiO <sub>2</sub> ≤ 100 mm Hg with PEEP ≥ 5 cm H <sub>2</sub> O	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>	Yes <input type="checkbox"/>
<del>Does</del> <u>Has</u> the patient developed ARDS?	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>	Yes <input type="checkbox"/> No <input type="checkbox"/>

Abbreviations: CPAP, continuous positive airway pressure; FiO<sub>2</sub>, fraction of inspired oxygen; PaO<sub>2</sub>, partial pressure of arterial oxygen; PEEP, positive end-expiratory pressure.

### PCT determination

Serum PCT levels were measured ~~by using~~ a highly sensitive and specific commercially available immunoluminometric assay kit (Vidasbrahms PCT, mini VIDS, Italy) according to the manufacturer's recommendation. Quantitative measurement allowed ~~the~~ determination of PCT concentrations ranging from 0.05 to 200 ng/ml.

### Study endpoints

The primary endpoint is ~~the~~ incidence of moderate to severe ARDS.

~~Secondary-~~The secondary endpoints include ~~the following~~:

- 1) The duration of mechanical ventilation;
- 2) The length of ICU stay;
- 3) Complications after surgery.

### Sample size

Primarily, we expect the incidence of moderate to severe ARDS ~~is higherto be~~ ~~increased~~ in the PCT elevated group ~~than in~~ ~~compared with~~ the control group.

Previous investigations ~~showed indicate~~ the overall morbidity of moderate to severe

ARDS was ~~around 0~~ ~~approximately~~ 0.5%-2% of patients ~~underwent~~ ~~undergoing~~

cardiac surgery.[1-3] Our pilot study ~~showed~~ ~~revealed~~ that the incidence could be as

high as 15% in ~~the~~ patients with elevated PCT levels. Using the Power and Sample

Size Calculation program, ~~we will need to investigate~~ 64 exposure subjects and 64

1  
2  
3  
4  
5  
6 control subjects [must be investigated](#) to be able to reject the null hypothesis. The ~~Type~~  
7 ~~type~~ I error probability ( $\alpha$ ) ~~with for~~ testing ~~this our~~ null hypothesis is 0.05, and ~~Type~~  
8 ~~the type~~ II error probability ( $\beta$ ) is 0.2.  
9  
10  
11  
12

### 13 14 15 **Statistical analysis**

16  
17  
18 Baseline characteristics ~~will be were~~ [summarized summarised by using](#) univariate  
19 analyses. Categorical variables ~~will be are~~ presented as numbers and percentages, and  
20 ~~analyzed analysed by using~~ the  $\chi^2$ -test. Continuous variables ~~will be checked are~~  
21 ~~assessed~~ for normal distribution and presented as means and standard deviations or  
22 medians and inter-quartile ranges as appropriate. ~~Comparison of e~~Continuous  
23 variables ~~will be performed by are compared~~ using ~~the~~ Student's t-test for normally  
24 distributed variables and the Mann-Whitney U test for non-normally distributed  
25 variables. All tests of significance ~~will be were~~ [two sided and conducted](#) at the 5%  
26 significance level, ~~and two sided~~. Subgroup analysis ~~will be was~~ performed to  
27 illustrate the ~~affection effects~~ of different types of surgery. Analyses are performed ~~by~~  
28 using SPSS 19.0 (IBM Corporation, New York, USA).  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Ethical aspects and informed consent

The study protocol and consent forms were approved on August 7th, 2014 by the Institutional Review Board of Fujian Provincial Hospital. The study was registered on August 8th, 2014 at ~~the~~ ClinicalTrials.org (ChiCTR-OCH-14005076).

After patient's eligibility for the study is confirmed, the study coordinator ~~will be~~ introduced to the family. The surgeon ~~will make sure~~ ensures that the family ~~knows the~~ ~~credentials of~~ is aware of the study coordinator's credentials, and ~~says~~ indicates that this ~~person individual is going to~~ will discuss ~~a~~ the research program being conducted, and ~~that~~ the patient is qualified to ~~do so~~ participate. Every relevant aspect of the project ~~will be~~ described. The study coordinator ~~will stop~~ frequently, ~~pauses to~~ ask if there are any questions, and requests that the family repeat ~~back in their own words~~ ~~what is the topic~~ being discussed ~~in their own words~~, to ~~make sure~~ ensure that they understand. The study coordinator ~~will be~~ especially careful to assure the family that they are free to decline consent without consequences and that they can withdraw consent at any time without ~~impact on~~ impacting treatment. Family members ~~will~~ ~~be~~ provided ~~with~~ contact information for the study coordinator, local co-investigator and the local Ethical Committee. Written consent ~~will be~~ obtained in the presence of a witness.

### Dissemination plan

~~Results of the~~ ~~The~~ study results will be submitted to ~~an~~ international peer reviewed journal. Results will also be presented at national and international conferences

Formatted: Highlight

1  
2  
3  
4  
5  
6 relevant to [the](#) subject fields. We will also consider ~~disseminate~~ disseminating the  
7  
8 results to the participants.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Formatted: Highlight

**Authors' contributions**

HC and RGY participated in the ~~design of the~~ study [design](#) and drafted the manuscript.

ZBC participated in the ~~design of the~~ study [design](#). All authors edited the manuscript and read and approved the final manuscript.

**Funding statement:**

This work was supported by grants from the National Clinical Key Specialty (2011170). The funders had no role in study design, data collection and analysis, decision to publish, or ~~preparation of the~~ manuscript [preparation](#).

**Competing interests**

The authors declare that they have no competing interests.

## References

1. Milot J, Perron J, Lacasse Y, Letourneau L, Cartier PC, Maltais F. Incidence and predictors of ARDS after cardiac surgery. *Chest* 2001;**119**(3):884-8
2. Christenson JT, Aeberhard JM, Badel P, et al. Adult respiratory distress syndrome after cardiac surgery. *Cardiovascular surgery (London, England)* 1996;**4**(1):15-21
3. Kaul TK, Fields BL, Riggins LS, Wyatt DA, Jones CR, Nagle D. Adult respiratory distress syndrome following cardiopulmonary bypass: incidence, prophylaxis and management. *The Journal of cardiovascular surgery* 1998;**39**(6):777-81
4. Stephens RS, Shah AS, Whitman GJ. Lung injury and acute respiratory distress syndrome after cardiac surgery. *The Annals of thoracic surgery* 2013;**95**(3):1122-9 doi: 10.1016/j.athoracsur.2012.10.024[published Online First: Epub Date]].
5. Weissman C. Pulmonary complications after cardiac surgery. *Seminars in cardiothoracic and vascular anesthesia* 2004;**8**(3):185-211
6. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. *The New England journal of medicine* 2005;**353**(16):1685-93 doi: 10.1056/NEJMoa050333[published Online First: Epub Date]].
7. Prat C, Ricart P, Ruyra X, et al. Serum concentrations of procalcitonin after cardiac surgery. *Journal of cardiac surgery* 2008;**23**(6):627-32 doi: 10.1111/j.1540-8191.2008.00658.x[published Online First: Epub Date]].
8. Hennein HA, Ebba H, Rodriguez JL, et al. Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. *The Journal of thoracic and cardiovascular surgery* 1994;**108**(4):626-35
9. Rocke DA, Gaffin SL, Wells MT, Koen Y, Brock-Utine JG. Endotoxemia associated with cardiopulmonary bypass. *The Journal of thoracic and cardiovascular surgery* 1987;**93**(6):832-7
10. Franke A, Lante W, Fackeldey V, et al. Pro-inflammatory cytokines after different kinds of cardio-thoracic surgical procedures: is what we see what we know? *European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery* 2005;**28**(4):569-75 doi: 10.1016/j.ejcts.2005.07.007[published Online First: Epub Date]].
11. Assicot M, Bohuon C, Gendrel D, Raymond J, Carsin H, Guilbaud J. High serum procalcitonin concentrations in patients with sepsis and infection. *The Lancet* 1993;**341**(8844):515-18
12. Reinhart K, Karzai W, Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. *Intensive care medicine* 2000;**26**(9):1193-200
13. Kallel S, Abid M, Jarraya A, et al. [Kinetics, diagnostic and prognostic value of procalcitonin after cardiac surgery]. *Annales de biologieclinique* 2012;**70**(5):567-80 doi: 10.1684/abc.2012.0745[published Online First: Epub Date]].
14. Dorge H, Schondube FA, Dorge P, Seipelt R, Voss M, Messmer BJ. Procalcitonin is a valuable prognostic marker in cardiac surgery but not specific for infection. *The Thoracic and cardiovascular surgeon* 2003;**51**(6):322-6 doi: 10.1055/s-2003-45425[published Online First: Epub Date]].
15. Kallel S, Jmel W, Jarraya A, Abdenadher M, Frikha I, Karouia A. The role of procalcitonin and N-terminal pro-B-type natriuretic peptide in predicting outcome after cardiac surgery.



1  
2  
3  
4  
5  
6 Perfusion 2012;**27**(6):504-11 doi: 10.1177/0267659112454155[published Online First: Epub  
7 Date]].

- 8  
9 16. AHA medical/scientific statement. 1994 revisions to classification of functional capacity and  
10 objective assessment of patients with diseases of the heart. Circulation 1994;**90**(1):644-5  
11  
12 17. Gaies MG, Gurney JG, Yen AH, et al. Vasoactive-inotropic score as a predictor of morbidity and  
13 mortality in infants after cardiopulmonary bypass. Pediatric critical care medicine : a journal  
14 of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and  
15 Critical Care Societies 2010;**11**(2):234-8 doi: 10.1097/PCC.0b013e3181b806fc[published  
16 Online First: Epub Date]].  
17  
18 18. Ranieri VM, Rubenfeld GD, Thompson BT, et al. Acute respiratory distress syndrome: the Berlin  
19 Definition. JAMA : the journal of the American Medical Association 2012;**307**(23):2526-33 doi:  
20 10.1001/jama.2012.5669[published Online First: Epub Date]].  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60